<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="862d96cb-5fd7-8e42-bc82-b4645975cfa1"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information
needed to use TARGINIQ™ ER safely and effectively.  See full prescribing
information for TARGINIQ ER.<br/>
      <br/>TARGINIQ ER (oxycodone
hydrochloride and naloxone hydrochloride extended-release tablets),
for oral use, CII<br/>Initial U.S. Approval:  2014</title>
   <effectiveTime value="20161222"/>
   <setId root="98e70c9c-fa3c-e63f-41d4-dac3c6fec51d"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="932323652" root="1.3.6.1.4.1.519.1"/>
            <name>Purdue Pharma LP</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="932323652" root="1.3.6.1.4.1.519.1"/>
                  <name>Purdue Pharma LP</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="132080875" root="1.3.6.1.4.1.519.1"/>
                        <name>Purdue Pharmaceuticals L.P.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59011-521" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59011-522" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59011-520" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="5547c7bc-b4ab-96b1-92d3-1b32988d8ccb"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20161222"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59011-521" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>TARGINIQ<suffix>ER</suffix>
                        </name>
                        <formCode code="C42930" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Oxycodone hydrochloride/naloxone hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="20" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C1ENJ2TE6C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OXYCODONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CD35PMG570" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OXYCODONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="10" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F850569PQR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NALOXONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="36B82AMQ7N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NALOXONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2KR89I4H1Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOLS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59011-521-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA205777" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200101"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="10" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">ONX;20</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59011-520" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>TARGINIQ<suffix>ER</suffix>
                        </name>
                        <formCode code="C42930" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Oxycodone hydrochloride/naloxone hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="10" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C1ENJ2TE6C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OXYCODONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CD35PMG570" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OXYCODONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="5" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F850569PQR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NALOXONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="36B82AMQ7N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NALOXONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2KR89I4H1Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOLS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59011-520-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA205777" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200101"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="5" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">ONX;10</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59011-522" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>TARGINIQ<suffix>ER</suffix>
                        </name>
                        <formCode code="C42930" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Oxycodone hydrochloride/naloxone hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="40" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="C1ENJ2TE6C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OXYCODONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="CD35PMG570" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>OXYCODONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="20" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="F850569PQR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NALOXONE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="36B82AMQ7N" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NALOXONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2KR89I4H1Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3WJQ0SDW1A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOLS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59011-522-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20200101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA205777" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20200101"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CE" code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" value="14" unit="mm"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">ONX;40</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CII"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_0">
               <id root="974d0391-fc60-1778-d53a-daf770e90859"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="bold">WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY
DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME;
CYTOCHROME P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH
BENZODIAZEPINES OR OTHER CNS DEPRESSANTS</content>
               </title>
               <text>
                  <paragraph ID="p711281406669176">
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline">Addiction, Abuse, and Misuse</content>
                           <br/>TARGINIQ<sup>TM</sup> ER exposes patients and other users to the risks
of opioid addiction, abuse, and misuse, which can lead to overdose
and death.  Assess each patient’s risk prior to prescribing TARGINIQ
ER and monitor all patients regularly for the development of these
behaviors and conditions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)].</content>
                        </content>
                     </content>
                  </paragraph>
                  <paragraph ID="p768634341406730694">
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline">Life-Threatening Respiratory Depression</content>
                           <br/>Serious, life-threatening, or fatal respiratory depression
may occur with use of TARGINIQ ER.  Monitor for respiratory depression,
especially during initiation of TARGINIQ ER or following a dose increase.
 Instruct patients to swallow TARGINIQ ER tablets whole; crushing,
chewing, or dissolving TARGINIQ ER tablets can cause rapid release
and absorption of a potentially fatal dose of oxycodone <content styleCode="italics">[see
Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>.</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p768434341406730691">
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline">Accidental
Ingestion</content>
                           <br/>Accidental ingestion of even one
dose of TARGINIQ ER, especially by children, can result in a fatal
overdose of oxycodone <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>.</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p746654341406730689">
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline">Neonatal Opioid Withdrawal Syndrome</content>
                           <br/>Prolonged use of TARGINIQ ER during pregnancy can result in neonatal
opioid withdrawal syndrome, which may be life-threatening if not recognized
and treated, and requires management according to protocols developed
by neonatology experts.  If opioid use is required for a prolonged
period in a pregnant woman, advise the patient of the risk of neonatal
opioid withdrawal syndrome and ensure that appropriate treatment will
be available <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)]</content>.</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p746854341406730686">
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline">Cytochrome P450 3A4 Interaction</content>
                           <br/>The concomitant use of TARGINIQ ER with all cytochrome P450 3A4
inhibitors may result in an increase in oxycodone plasma concentrations,
which could increase or prolong adverse drug effects and may cause
potentially fatal respiratory depression.  In addition, discontinuation
of a concomitantly used cytochrome P450 3A4 inducer may result in
an increase in oxycodone plasma concentration.  Monitor patients receiving
TARGINIQ ER and any CYP3A4 inhibitor or inducer <content styleCode="italics">[see Warnings
and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>), Drug Interactions
(<linkHtml href="#Section_7">7</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>.</content>
                     </content>
                  </paragraph>
                  <paragraph ID="p11288851441480727577">
                     <content styleCode="xmChange">
                        <content styleCode="bold">
                           <content styleCode="underline">Risks From Concomitant Use With Benzodiazepines
Or Other CNS Depressants</content>
                           <br/>Concomitant use of
opioids with benzodiazepines or other central nervous system (CNS)
depressants, including alcohol, may result in profound sedation, respiratory
depression, coma, and death <content styleCode="italics">[see Warnings and Precautions
(<linkHtml href="#Section_5.5">5.5</linkHtml>), Drug Interactions (<linkHtml href="#Section_7">7</linkHtml>)]</content>.</content>
                     </content>
                  </paragraph>
                  <list listType="unordered" ID="l11057551441480727644" styleCode="Disc">
                     <item>
                        <content styleCode="xmChange">
                           <content styleCode="bold">Reserve concomitant prescribing
of TARGINIQ ER Injection and benzodiazepines or other CNS depressants
for use in patients for whom alternative treatment options are inadequate.</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="xmChange">
                           <content styleCode="bold">Limit dosages and durations to
the minimum required.</content>
                           <br/>
                           <content styleCode="bold">Follow patients for
signs and symptoms of respiratory depression and sedation.</content>
                        </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20161222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p2610281406669183">
                           <content styleCode="xmChange">
                              <content styleCode="bold">WARNING:
ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION;
ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME
P450 3A4 INTERACTION; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES
AND OTHER CNS DEPRESSANTS</content>
                           </content>
                        </paragraph>
                        <paragraph ID="p2811281406669185">
                           <content styleCode="xmChange">
                              <content styleCode="italics">
                                 <content styleCode="bold">See full prescribing information for complete boxed warning.</content>
                              </content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="l26614281406728743" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange">
                                 <content styleCode="bold">TARGINIQ ER exposes users to risks
of addiction, abuse and misuse, which can lead to overdose and death.
Assess patient’s risk before prescribing and monitor regularly for
these behaviors and conditions. (<linkHtml href="#Section_5.1">5.1</linkHtml>)</content>
                              </content>
                           </item>
                           <item>
                              <content styleCode="xmChange">
                                 <content styleCode="bold">Serious, life-threatening, or fatal
respiratory depression may occur.  Monitor closely, especially upon
initiation or following a dose increase.  Instruct patients to swallow
TARGINIQ ER tablets whole to avoid exposure to a potentially fatal
dose of oxycodone. (<linkHtml href="#Section_5.2">5.2</linkHtml>)</content>
                              </content>
                           </item>
                           <item>
                              <content styleCode="xmChange">
                                 <content styleCode="bold">Accidental ingestion of TARGINIQ
ER, especially by children, can result in a fatal overdose of oxycodone.
(<linkHtml href="#Section_5.2">5.2</linkHtml>)</content>
                              </content>
                           </item>
                           <item>
                              <content styleCode="xmChange">
                                 <content styleCode="bold">Prolonged use of TARGINIQ ER during
pregnancy can result in neonatal opioid withdrawal syndrome, which
may be life-threatening if not recognized and treated.  If prolonged
opioid use is required in a pregnant woman, advise the patient of
the risk of neonatal opioid withdrawal syndrome and ensure that appropriate
treatment will be available. (<linkHtml href="#Section_5.3">5.3</linkHtml>)</content>
                              </content>
                           </item>
                           <item>
                              <content styleCode="xmChange">
                                 <content styleCode="bold">Concomitant use with CYP3A4 inhibitors
(or discontinuation of CYP3A4 inducers) can result in a fatal overdose
of oxycodone. (<linkHtml href="#Section_5.4">5.4</linkHtml>)</content>
                              </content>
                           </item>
                           <item>
                              <content styleCode="xmChange">
                                 <content styleCode="bold">Concomitant use of opioids with
benzodiazepines or other central nervous system (CNS) depressants,
including alcohol, may result in profound sedation, respiratory depression,
coma, and death. Reserve concomitant prescribing for use in patients
for whom alternative treatment options are inadequate; limit dosages
and durations to the minimum required; and follow patients for signs
and symptoms of respiratory depression and sedation. (<linkHtml href="#Section_5.5">5.5</linkHtml>, <linkHtml href="#Section_7">7</linkHtml>)</content>
                              </content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_00">
               <id root="cd149bf4-69e9-bfa0-ab20-2a86e1f2ea93"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title/>
               <effectiveTime value="20161222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table ID="t527105144" width="100%">
                           <colgroup>
                              <col/>
                              <col/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td>Box Warning</td>
                                 <td>12/2016</td>
                              </tr>
                              <tr>
                                 <td>Indications and Usage (<linkHtml href="#Section_1">1</linkHtml>)</td>
                                 <td>12/2016</td>
                              </tr>
                              <tr>
                                 <td>Dosage and Administration (<linkHtml href="#Section_2">2</linkHtml>)</td>
                                 <td>12/2016</td>
                              </tr>
                              <tr>
                                 <td>Warning and Precautions (<linkHtml href="#Section_5">5</linkHtml>)</td>
                                 <td>12/2016</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="d8b061a6-f47c-95ab-85a9-9514bfcbdac2"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph ID="p798014341406731041">
                     <content styleCode="xmChange">TARGINIQ ER is indicated
for the management of pain severe enough to require daily, around-the-clock,
long-term opioid treatment and for which alternative treatment options
are inadequate.</content>
                  </paragraph>
                  <paragraph ID="p798234341406731056">
                     <content styleCode="xmChange">
                        <content styleCode="underline">Limitations
of Use</content>
                     </content>
                  </paragraph>
                  <br/>
                  <list listType="unordered" ID="l819724341406731064" styleCode="Disc">
                     <item>
                        <content styleCode="xmChange">Because of the risks of addiction, abuse,
and misuse with opioids, even at recommended doses, and because of
the greater risks of overdose and death with extended-release opioid
formulations <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>, reserve TARGINIQ ER for
use in patients for whom alternative treatment options (e.g., non-opioid
analgesics or immediate-release opioids) are ineffective, not tolerated,
or would be otherwise inadequate to provide sufficient management
of pain.</content>
                     </item>
                     <item>
                        <content styleCode="xmChange">TARGINIQ ER is not indicated as an as-needed
(prn) analgesic.</content>
                     </item>
                     <item>
                        <content styleCode="xmChange">The maximum total daily dose of TARGINIQ
ER should not exceed 80 mg/40 mg (40 mg/20 mg q12h) because higher
doses may be associated with symptoms of opioid withdrawal or decreased
analgesia <content styleCode="italics">[see Warnings and Precautions <linkHtml href="#Section_5.12">5.12</linkHtml>]</content>.</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20161222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p7702281406728819">
                           <content styleCode="xmChange">TARGINIQ ER is
a combination product consisting of oxycodone, an opioid agonist,
and naloxone, an opioid antagonist, indicated for the management of
pain severe enough to require daily, around-the-clock, long-term opioid
treatment and for which alternative treatment options are inadequate.
(<linkHtml href="#Section_1">1</linkHtml>)</content>
                        </paragraph>
                        <br/>
                        <paragraph ID="p7713281406728828">
                           <content styleCode="xmChange">
                              <content styleCode="underline">Limitations
of Use</content>
                           </content>
                        </paragraph>
                        <list listType="unordered" ID="l7802281406728834" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange">Because of the risks of addiction, abuse,
and misuse with opioids, even at recommended doses, and because of
the greater risks of overdose and death with extended-release opioid
formulations, reserve TARGINIQ ER for use in patients for whom alternative
treatment options (e.g., non-opioid analgesics or immediate-release
opioids) are ineffective, not tolerated, or would be otherwise inadequate
to provide sufficient management of pain. (<linkHtml href="#Section_1">1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">TARGINIQ ER is not indicated as an as-needed
(prn) analgesic. (<linkHtml href="#Section_1">1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Total daily dose should not exceed 80
mg/40 mg (40 mg/20 mg q12h) because higher doses may be associated
with symptoms of opioid withdrawal. (<linkHtml href="#Section_1">1</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="daf09796-daa5-b923-bd6e-69cbccc60293"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20161222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l10531281406729013" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange">To be prescribed only by healthcare providers
knowledgeable in use of potent opioids for management of chronic pain.
(<linkHtml href="#Section_2.1">2.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">A single dose of TARGINIQ ER greater
than 40 mg/20 mg or a total daily dose greater than 80 mg/40 mg are
only for use in patients in whom tolerance to an opioid of comparable
potency has been established.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Patients considered opioid tolerant are
those taking, for one week or longer, at least 60 mg oral morphine
per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone
per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per
day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another
opioid. (<linkHtml href="#Section_2.1">2.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Use the lowest effective dosage for the
shortest duration consistent with individual patient treatment goals.
(<linkHtml href="#Section_2.1">2.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Individualize dosing based on the severity
of pain, patient response, prior analgesic experience, and risk factors
for addiction, abuse, and misuse. (<linkHtml href="#Section_2.1">2.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Instruct patients to swallow tablets
intact  and not to cut, break, chew, crush, or dissolve tablets (risk
of potentially fatal overdose). (<linkHtml href="#Section_2.1">2.1</linkHtml>, <linkHtml href="#Section_5.1">5.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">For opioid-naïve and opioid non-tolerant
patients, initiate with 10 mg/5 mg tablets orally every 12 hours.
(<linkHtml href="#Section_2.1">2.1</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Mild Hepatic Impairment: Reduce the starting
dose of TARGINIQ ER to 1/3 to 1/2 the usual starting dose in patients
with mild hepatic impairment. (<linkHtml href="#Section_8.7">8.7</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Renal Impairment:  Reduce the initial
dose to 1/2 the usual dose when administering TARGINIQ ER to patients
with renal impairment. (<linkHtml href="#Section_8.8">8.8</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Do not abruptly discontinue TARGINIQ
ER in a physically dependent patient. (<linkHtml href="#Section_2.5">2.5</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="ff50c170-f7dd-69c5-115c-95df461aa17a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Dosing
and Administration Instructions</title>
                     <text>
                        <paragraph ID="p847614341406731197">
                           <content styleCode="xmChange">TARGINIQ ER should be
prescribed only by healthcare professionals who are knowledgeable
in the use of potent opioids for the management of chronic pain.</content>
                        </paragraph>
                        <paragraph ID="p847414341406731196">
                           <content styleCode="xmChange">A single dose of TARGINIQ ER greater than 40 mg/20 mg or a total
daily dose greater than 80 mg/40 mg are only for use in patients in
whom tolerance to an opioid of comparable potency has been established.
 Patients who are opioid tolerant are those receiving, for one week
or longer, at least 60 mg oral morphine per day, 25 mcg transdermal
fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone
per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per
day, or an equianalgesic dose of another opioid.</content>
                        </paragraph>
                        <list listType="unordered" ID="l325601351441480727830" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange">Use the lowest effective dosage for the
shortest duration consistent with individual patient treatment goals <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>.Initiate the dosing regimen for each patient individually,
taking into account the patient's severity of pain, patient response,
prior analgesic treatment experience, and risk factors for addiction,
abuse, and misuse <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Monitor patients closely for respiratory
depression, especially within the first 24-72 hours of initiating
therapy with TARGINIQ ER and following dosage increases with TARGINIQ
and adjust the dosage accordingly <content styleCode="italics">[see Warnings and Precautions
(<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>.</content>
                           </item>
                        </list>
                        <paragraph ID="p847214341406731195">
                           <content styleCode="xmChange">Instruct
patients to swallow TARGINIQ ER tablets whole <content styleCode="italics">[see Patient
Counseling Information (<linkHtml href="#Section_17">17</linkHtml>)]. </content>Crushing, chewing, or dissolving TARGINIQ ER tablets will result
in uncontrolled delivery of oxycodone and can lead to overdose or
death <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>.</content>
                        </paragraph>
                        <paragraph ID="p847014341406731194">
                           <content styleCode="xmChange">TARGINIQ ER is administered
orally every 12 hours.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="ad490608-6b0b-6ccc-4293-41a79642aa2c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Initial Dosage</title>
                     <text>
                        <paragraph ID="p1078714341406733023">
                           <content styleCode="xmChange">
                              <content styleCode="underline">Use of TARGINIQ ER as the First Opioid Analgesic (opioid-naïve patients)</content>
                              <br/>Initiate treatment with TARGINIQ ER with one 10 mg/5
mg tablet orally every 12 hours.</content>
                        </paragraph>
                        <paragraph ID="p1078514341406733021">
                           <content styleCode="xmChange">
                              <content styleCode="underline">Use of TARGINIQ
ER in Patients who are not Opioid Tolerant (opioid non-tolerant patients)</content>
                              <br/>The starting dosage for patients who are not opioid tolerant
is TARGINIQ ER 10 mg/5 mg orally every 12 hours.<br/>Use of
higher starting doses in patients who are not opioid tolerant may
cause fatal respiratory depression.</content>
                        </paragraph>
                        <paragraph ID="p1078234341406733018">
                           <content styleCode="xmChange">
                              <content styleCode="underline">Conversion from Other Oral Oxycodone Formulations to TARGINIQ ER</content>
                              <br/>Patients receiving other oral oxycodone formulations
may be converted to TARGINIQ ER by administering one-half of the patient's
total daily oral oxycodone dose as TARGINIQ ER every 12 hours.</content>
                        </paragraph>
                        <paragraph ID="p1104544341406733314">
                           <content styleCode="xmChange">
                              <content styleCode="underline">Conversion from Other Opioids to TARGINIQ ER</content>
                              <br/>Discontinue all other around-the-clock opioid drugs when
TARGINIQ ER therapy is initiated.</content>
                        </paragraph>
                        <paragraph ID="p287001051441480728041">
                           <content styleCode="xmChange">There is inter-patient
variability in the relative potency of opioid drugs and opioid formulations.
 Therefore, a conservative approach is advised when determining the
total daily dosage of TARGINIQ ER. It is safer to underestimate a
patient’s 24-hour oral oxycodone requirements and provide rescue medication
(e.g., immediate-release opioid) than to overestimate the 24-hour
oral oxycodone dosage and manage an adverse reaction due to an overdose.</content>
                        </paragraph>
                        <paragraph ID="p1104344341406733312">
                           <content styleCode="xmChange">In a TARGINIQ ER clinical trial with an open-label titration period,
patients were converted from their prior opioid to TARGINIQ ER using
both Table 1 and Table 2 below.</content>
                        </paragraph>
                        <paragraph ID="p1104144341406733311">
                           <content styleCode="xmChange">Consider the following
when using the information in Table 1 and Table 2:</content>
                        </paragraph>
                        <list listType="unordered" ID="l245971051441480728079" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange">These are not tables of equianalgesic
doses. The conversion factors in Table 1 are only for the conversion <content styleCode="underline">from</content> one of the listed oral opioid analgesics <content styleCode="underline">to</content> the Equivalent Daily Oral Morphine Dose.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">The conversion factors in Table 2 are
only for conversion <content styleCode="underline">from</content> the calculated Equivalent
Daily Oral Morphine Dose <content styleCode="underline">to</content> TARGINIQ ER.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">The tables <content styleCode="underline">cannot</content> be used to convert <content styleCode="underline">from</content> TARGINIQ ER to another
opioid.  Doing so will result in an overestimation of the dose of
the new opioid and may result in a fatal overdose.</content>
                           </item>
                        </list>
                        <paragraph ID="p243301451441480728121">
                           <content styleCode="xmChange">Convert
patients from their previous opioid to TARGINIQ ER as follows:</content>
                        </paragraph>
                        <list listType="ordered" ID="l24356851441480728143" styleCode="Arabic">
                           <item>
                              <content styleCode="xmChange">Using Table 1, calculate the Equivalent
Daily Oral Morphine Dose by multiplying the current total daily dose
of each opioid by the appropriate Conversion Factor.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Using Table 2, determine the starting
dose of TARGINIQ ER by reading across from the appropriate Equivalent
Daily Dose of Oral Morphine range, rounding down, if necessary.</content>
                           </item>
                        </list>
                        <table ID="t3023645144" border="0" width="100%">
                           <caption>Table 1.  Converting the Current Total Daily Oral Opioid
Dose(s) to the Equivalent Daily Oral Morphine Dose</caption>
                           <colgroup>
                              <col/>
                              <col/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Current Oral Opioid</content>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Conversion Factor</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">Morphine</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">1</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">Codeine</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">0.3</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">Hydrocodone</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">1.8</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">Hydromorphone</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">8</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">Methadone<sup>†</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">3</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">Oxycodone</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">2</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">Oxymorphone</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">4</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">Tramadol*</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">Tapentadol</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">0.3</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" colspan="2">
                                    <content styleCode="xmChange">
                                       <sup>† </sup> See note on conversion of methadone
to TARGINIQ ER below<br/>* patients on tramadol should be initiated
on the lowest available TARGINIQ ER dose, 10 mg/5 mg every 12 hours</content>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <table ID="t283075144" border="0" width="70%">
                           <caption>Table 2. Initial TARGINIQ ER Dose</caption>
                           <colgroup>
                              <col width="29*"/>
                              <col width="70*"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Equivalent Daily Oral Morphine Dose</content>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule" align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Recommended TARGINIQ ER Starting Dose</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="xmChange">20 to &lt;70
mg</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="xmChange">10 mg/5 mg
every 12 hours (ie. 20 mg oxycodone daily)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="xmChange">70 to &lt;110
mg</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="xmChange">20 mg/10
mg every 12 hours (ie. 40 mg oxycodone daily)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="xmChange">110 to &lt;150
mg</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="xmChange">30 mg/15
mg every 12 hours (ie. 60 mg oxycodone daily)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="xmChange">150 to 160
mg</content>
                                 </td>
                                 <td styleCode="Toprule Botrule Rrule Lrule">
                                    <content styleCode="xmChange">40 mg/20
mg every 12 hours (ie. 80 mg oxycodone daily)</content>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p2565451441480728555">
                           <content styleCode="xmChange">Example
conversion from a single opioid to TARGINIQ ER:</content>
                        </paragraph>
                        <paragraph ID="p2564551441480728558">
                           <content styleCode="xmChange">Step 1: A patient receiving oxymorphone at a total daily dose of
10 mg would equate to an Equivalent Daily Oral Morphine Dose of 40
mg (10 mg x 4; Table 1).</content>
                        </paragraph>
                        <paragraph ID="p2560551441480728574">
                           <content styleCode="xmChange">Step 2: Based on Table
2, the starting dose is TARGINIQ ER 10 mg/5 mg every 12 hours.</content>
                        </paragraph>
                        <list listType="unordered" ID="l2589251441480728577" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange">For patients on a regimen of more than
one opioid, use Table 1 to calculate the Equivalent Daily Oral Morphine
dose for each opioid and sum the totals, then use Table 2 to obtain
the starting dose of TARGINIQ ER.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Round down, if necessary, to the appropriate
TARGINIQ ER tablet strengths available.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Monitor patients for signs and symptoms
of opioid withdrawal or for signs of over-sedation/toxicity after
converting patients to TARGINIQ ER.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Titrate appropriately to a stable and
tolerated dose.</content>
                           </item>
                        </list>
                        <paragraph ID="p2346451441480728610">
                           <content styleCode="xmChange">Close
observation and frequent titration are warranted until pain management
is stable on the new opioid. Monitor patients for signs and symptoms
of opioid withdrawal and for signs of oversedation/toxicity after
converting patients to TARGINIQ ER.</content>
                        </paragraph>
                        <paragraph ID="p2349251441480728611">
                           <content styleCode="xmChange">
                              <content styleCode="underline">Conversion from Methadone to TARGINIQ ER</content>
                              <br/>Close
monitoring is of particular importance when converting from methadone
to other opioid agonists.  The ratio between methadone and other opioid
agonists may vary widely as a function of previous dose exposure.
 Methadone has a long half-life and can accumulate in the plasma.</content>
                        </paragraph>
                        <paragraph ID="p2051551441480728646">
                           <content styleCode="xmChange">
                              <content styleCode="underline">Conversion from Transdermal Fentanyl to TARGINIQ ER</content>
                              <br/>Treatment with, TARGINIQ ER can be initiated after the
transdermal fentanyl patch has been removed for at least 18 hours.
 Although there has been no systematic assessment of such conversion,
start with a conservative conversion: substitute 10 mg/5 mg of TARGINIQ
ER every 12 hours for each 25 mcg/hr fentanyl transdermal patch. 
Follow the patient closely during conversion from transdermal fentanyl
to TARGINIQ ER, as there is limited documented experience with this
conversion.</content>
                        </paragraph>
                        <paragraph ID="p2058551441480728667">
                           <content styleCode="xmChange">
                              <content styleCode="underline">Conversion
from Transdermal Buprenorphine to TARGINIQ ER</content>
                              <br/>For patients receiving transdermal buprenorphine (<content styleCode="underline">&lt;</content>
                              <content styleCode="bold"/>20 mcg/hr), the recommended starting dose is TARGINIQ
ER 10 mg/5 mg every 12 hours. Follow the patient closely during conversion
from transdermal buprenorphine to TARGINIQ ER, as there is limited
experience with this conversion.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="114923c7-b6e4-8371-08da-54c4ba1eb1c8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Titration and Maintenance
of Therapy</title>
                     <text>
                        <paragraph ID="p1103584341406733309">
                           <content styleCode="xmChange">Individually titrate TARGINIQ ER to a dose that
provides adequate analgesia and minimizes adverse reactions.  Continually
reevaluate patients receiving TARGINIQ ER to assess the maintenance
of pain control and the relative incidence of adverse reactions, as
well as monitoring for the development of addiction, abuse, and misuse <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>.  Frequent communication is important among the prescriber,
other members of the healthcare team, the patient, and the caregiver/family
during periods of changing analgesic requirements, including initial
titration.  During chronic therapy, periodically reassess the continued
need for the use of opioid analgesics.</content>
                        </paragraph>
                        <paragraph ID="p24339651441480728747">
                           <content styleCode="xmChange">Patients
who experience breakthrough pain may require a dosage adjustment of
TARGINIQ ER or may need rescue medication with an appropriate dose
of an immediate-release analgesic.  If the level of pain increases
after dose stabilization, attempt to identify the source of increased
pain before increasing the TARGINIQ ER dose.</content>
                        </paragraph>
                        <paragraph ID="p2076451441480728749">
                           <content styleCode="xmChange">As a guideline,
the dose of TARGINIQ ER can be up-titrated from the current dose by
increasing the dose 10 mg/5 mg q12h every 1 to 2 days as needed based
on efficacy, safety, and tolerability.  The total daily dose of TARGINIQ
ER should not exceed 80 mg/40 mg (40 mg/20 mg q12h).</content>
                        </paragraph>
                        <paragraph ID="p2074851441480728750">
                           <content styleCode="xmChange">The highest total daily dose of TARGINIQ ER studied in the main clinical
program is 80 mg/40 mg (40 mg/20 mg twice daily).  Total daily doses
above 80 mg/40 mg have not been studied sufficiently to ensure patient
safety and may be associated with symptoms of opioid withdrawal or
decreased analgesia.</content>
                        </paragraph>
                        <paragraph ID="p20591551441480728765">
                           <content styleCode="xmChange">If unacceptable opioid-related
adverse reactions are observed, consider reducing the dosage.  Adjust
the dosage to obtain an appropriate balance between management of
pain and opioid-related adverse reactions.</content>
                        </paragraph>
                        <paragraph ID="p2083351441480728775">
                           <content styleCode="xmChange">There are
no well-controlled clinical studies evaluating the safety and efficacy
with dosing more frequently than every 12 hours.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.4">
                     <id root="fae4f46b-c014-9a00-cf7a-410fee7fca41"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage Modifications
with Concomitant Use of Central Nervous System Depressants</title>
                     <text>
                        <paragraph ID="p1126844341406733413">
                           <content styleCode="xmChange">If the patient
is currently taking a central nervous system (CNS) depressant and
the decision is made to begin TARGINIQ ER, start with one-third to
one-half the recommended starting dosage of TARGINIQ ER, consider
using a lower dosage of the concomitant CNS depressant, and monitor
patients for signs of respiratory depression, sedation, and hypotension <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>), Drug Interactions (<linkHtml href="#Section_7">7</linkHtml>)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.5">
                     <id root="7c0a47e2-67ab-43dd-30e4-dcc6fa16d1e1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dosage Modifications
in Patients with Mild Hepatic Impairment</title>
                     <text>
                        <paragraph ID="p1127224341406733415">
                           <content styleCode="xmChange">TARGINIQ ER is contraindicated
in patients with moderate and severe hepatic impairment. When administering
TARGINIQ ER to patients with mild hepatic impairment, reduce the dose
to one-third to one-half the usual starting dose followed by careful
dose titration. Monitor for signs of respiratory depression, sedation,
and hypotension <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.7">8.7</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.6">
                     <id root="26feb1d8-ee08-a22a-961a-a760cbf563a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage Modifications
in Patients with Renal Impairment</title>
                     <text>
                        <paragraph ID="p640084341406734402">
                           <content styleCode="xmChange">When administering TARGINIQ
ER to patients with renal impairment, reduce the initial dose to one-half
the usual starting dose followed by careful dose titration. Monitor
for signs of respiratory depression, sedation, and hypotension <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.8">8.8</linkHtml>), Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.7">
                     <id root="6efcd2c3-6ba6-a082-bc9a-0f7c0bc91731"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.7 Discontinuation of TARGINIQ ER</title>
                     <text>
                        <paragraph ID="p23853651441480728981">
                           <content styleCode="xmChange">When the patient no
longer requires therapy with TARGINIQ ER, taper the dose gradually
by 25% to 50 % every 2 to 4 days, while monitoring carefully for signs
and symptoms of withdrawal. If the patient develops these signs or
symptoms, raise the dose to the previous level and taper more slowly,
either by increasing the interval between decreases, decreasing the
amount of change in dose, or both.  Do not abruptly discontinue TARGINIQ
ER <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.12">5.12</linkHtml>), Drug Abuse and Dependence (<linkHtml href="#Section_9.3">9.3</linkHtml>)]</content>.</content>
                        </paragraph>
                        <paragraph ID="p3602351441480729015">
                           <content styleCode="xmChange">Table 3 presents a suggested
taper schedule that was used in a clinical trial to discontinue patients
from TARGINIQ ER:</content>
                        </paragraph>
                        <table ID="t360045144" border="1" width="100%">
                           <caption>Table 3.  Suggested Taper Schedule</caption>
                           <colgroup>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                              <col/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="12">
                                    <content styleCode="xmChange">* 30 mg/15 mg dose was achieved
by administering a 20 mg/10 mg + a 10 mg/5 mg tablet</content>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Botrule Rrule Lrule" colspan="2" rowspan="2">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Patient’s Dose of TARGINIQ ER</content>
                                    </content>
                                 </td>
                                 <td colspan="10">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Taper Dose (mg/mg)</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Day 1</content>
                                    </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Day 2</content>
                                    </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Day 3</content>
                                    </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Day 4</content>
                                    </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Day 5</content>
                                    </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Day 6</content>
                                    </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Day 7</content>
                                    </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Day 8</content>
                                    </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Day 9</content>
                                    </content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">
                                       <content styleCode="bold">Day 10</content>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2">
                                    <content styleCode="xmChange">10 mg/5 mg q12h</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">AM</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <content styleCode="xmChange">PM</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2">
                                    <content styleCode="xmChange">20 mg/10 mg q12h</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">AM</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <content styleCode="xmChange">PM</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2">
                                    <content styleCode="xmChange">30 mg/15 mg q12h*</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">AM</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <content styleCode="xmChange">PM</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td rowspan="2">
                                    <content styleCode="xmChange">40 mg/20 mg q12h</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">AM</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">30/15</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">30/15</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <content styleCode="xmChange">PM</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">30/15</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">30/15</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">20/10</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">10/5</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                                 <td align="center">
                                    <content styleCode="xmChange">-</content>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="f5fe1f7e-82a9-c4dc-f37a-4409e539c12e"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph ID="p3872551441480729591">Extended-release tablets: 10
mg/5 mg, 20 mg/10 mg, and 40 mg/20.</paragraph>
                  <list listType="unordered" ID="l1332294341406734530" styleCode="Disc">
                     <item>10 mg/5 mg film-coated extended-release tablets (capsule
shaped, white film-coated tablets debossed with “ONX” on one side
and “10” on the other)</item>
                     <item>20 mg/10 mg film-coated extended-release tablets (capsule
shaped, pink film-coated tablets debossed with “ONX” on one side and
“20” on the other)</item>
                     <item>40 mg/20 mg film-coated extended-release tablets (capsule
shaped, yellow film-coated tablets debossed with “ONX” on one side
and “40” on the other)</item>
                  </list>
               </text>
               <effectiveTime value="20161222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l132613281406729072" styleCode="Disc">
                           <item>Extended-release tablets: 10 mg/5 mg, 20 mg/10 mg, and 40
mg/20 mg (<linkHtml href="#Section_3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="687b8cb2-4f2b-bccb-1f21-f9e2870d2171"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph ID="p1359864341406734577">
                     <content styleCode="xmChange">TARGINIQ
ER is contraindicated in patients with:</content>
                  </paragraph>
                  <br/>
                  <list listType="unordered" ID="l1360524341406734586" styleCode="Disc">
                     <item>
                        <content styleCode="xmChange">Significant respiratory depression <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="xmChange">Acute or severe bronchial asthma in an
unmonitored setting or in the absence of resuscitative equipment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.6">5.6</linkHtml>)]</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="xmChange">Known or suspected gastrointestinal obstruction,
including paralytic ileus <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.10">5.10</linkHtml>)]</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="xmChange">Hypersensitivity (e.g., anaphylaxis)
to oxycodone or naloxone <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.2">6.2</linkHtml>)]</content>
                        </content>
                     </item>
                     <item>
                        <content styleCode="xmChange">Moderate to severe hepatic impairment <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12.2">12.2</linkHtml>)]</content>
                        </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20161222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l15674281406729122" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange">Significant respiratory depression (<linkHtml href="#Section_4">4</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Acute or severe bronchial asthma in an
unmonitored setting or in the absence of resuscitative equipment (<linkHtml href="#Section_4">4</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Known or suspected gastrointestinal obstruction,
including paralytic ileus (<linkHtml href="#Section_4">4</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Hypersensitivity to oxycodone or naloxone
(<linkHtml href="#Section_4">4</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">Moderate to severe hepatic impairment
(<linkHtml href="#Section_4">4</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="8af8d80b-a165-db1b-f7a7-3dc4c3e666f1"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20161222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l20781281406729211" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange">
                                 <content styleCode="underline">Life-Threatening Respiratory
Depression in Patients with Chronic Pulmonary Disease or in </content>Elderly, Cachectic, or Debilitated Patients: Monitor closely, particularly
during initiation and titration. (<linkHtml href="#Section_5.6">5.6</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">
                                 <content styleCode="underline">Adrenal Insufficiency</content>: If  diagnosed, treat with physiologic replacement of corticosteroids,
and  wean  patient off  of  the opioid. (<linkHtml href="#Section_5.7">5.7</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">
                                 <content styleCode="underline">Severe Hypotension</content>: Monitor during dose initiation and titration. Avoid use in patients
with circulatory shock. (<linkHtml href="#Section_5.8">5.8</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">
                                 <content styleCode="underline">Risks of Use in Patients with
Increased Intracranial Pressure, Head Injury, Brain Tumors, or Impaired
Consciousness</content>: Monitor for sedation and respiratory depression.
Avoid use of TARGINIQ ER in patients with impaired consciousness or
coma. (<linkHtml href="#Section_5.9">5.9</linkHtml>)</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">
                                 <content styleCode="underline">Withdrawal</content>: Symptoms
consistent with opioid withdrawal occurred in some patients in the
clinical trials.  Monitor patients for symptoms of withdrawal during
treatment with TARGINIQ ER. (<linkHtml href="#Section_5.12">5.12</linkHtml>)</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="677f39b2-7a6f-73a3-0d85-d25fe7bae0e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Addiction, Abuse, and Misuse</title>
                     <text>
                        <paragraph ID="p1433814341406734671">
                           <content styleCode="xmChange">TARGINIQ ER contains
oxycodone, a Schedule II controlled substance.  As an opioid, TARGINIQ
ER exposes users to the risks of addiction, abuse, and misuse.  Because
extended-release products such as TARGINIQ ER deliver the opioid over
an extended period of time, there is a greater risk for overdose and
death due to the larger amount of oxycodone present <content styleCode="italics">[see Drug
Abuse and Dependence (<linkHtml href="#Section_9">9</linkHtml>)]</content>.</content>
                        </paragraph>
                        <paragraph ID="p1433614341406734669">
                           <content styleCode="xmChange">Although the risk of addiction in any individual is unknown, it can
occur in patients appropriately prescribed TARGINIQ ER.  Addiction
can occur at recommended doses and if the drug is misused or abused.</content>
                        </paragraph>
                        <paragraph ID="p1434414341406734717">
                           <content styleCode="xmChange">Assess each patient’s risk for opioid addiction, abuse or misuse,
prior to prescribing TARGINIQ ER, and monitor all patients receiving
TARGINIQ ER for the development of these behaviors and conditions.
 Risks are increased in patients with a personal or family history
of substance abuse (including drug or alcohol abuse or addiction)
or mental illness (e.g., major depression).  The potential for these
risks should not, however, prevent the proper management of pain in
any given patient.  Patients at increased risk may be prescribed opioids
such as TARGINIQ ER, but use in such patients necessitates intensive
counseling about the risks and proper use of TARGINIQ ER along with
intensive monitoring for signs of addiction, abuse, and misuse.</content>
                        </paragraph>
                        <paragraph ID="p1434214341406734716">
                           <content styleCode="xmChange">Abuse or misuse of TARGINIQ ER by crushing, chewing, snorting, or
injecting the dissolved product will result in the uncontrolled delivery
of oxycodone and can result in overdose and death <content styleCode="italics">[see Overdosage
(<linkHtml href="#Section_10">10</linkHtml>)]</content>.</content>
                        </paragraph>
                        <paragraph ID="p1434014341406734714">
                           <content styleCode="xmChange">Opioids are sought by drug abusers and people with addiction disorders
and are subject to criminal diversion.  Consider these risks when
prescribing or dispensing TARGINIQ ER.  Strategies to reduce these
risks include prescribing the drug in the smallest appropriate quantity
and advising the patient on the proper disposal of unused drug <content styleCode="italics">[see Patient Counseling Information (<linkHtml href="#Section_17">17</linkHtml>)]</content>.  Contact local state professional licensing board or
state controlled substances authority for information on how to prevent
and detect abuse or diversion of this product.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="8e86fdac-26ee-4b3a-6474-5f50dc949e19"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Life-Threatening Respiratory Depression</title>
                     <text>
                        <paragraph ID="p1412814341406734668">
                           <content styleCode="xmChange">Serious, life-threatening,
or fatal respiratory depression has been reported with the use of
opioids, even when used as recommended.  Respiratory depression, if
not immediately recognized and treated, may lead to respiratory arrest
and death.  Management of respiratory depression may include close
observation, supportive measures, and use of opioid antagonists, depending
on the patient’s clinical status <content styleCode="italics">[see Overdosage (<linkHtml href="#Section_10">10</linkHtml>)]</content>.  Carbon dioxide (CO<sub>2</sub>) retention from opioid-induced respiratory depression
can exacerbate the sedating effects of opioids.</content>
                        </paragraph>
                        <paragraph ID="p1412614341406734667">
                           <content styleCode="xmChange">While serious, life-threatening, or fatal respiratory depression
can occur at any time during the use of TARGINIQ ER, the risk is greatest
during the initiation of therapy or following a dosage increase. 
Monitor patients closely for respiratory depression, especially within
the first 24-72 hours of initiating therapy and following dosage increases
of TARGINIQ ER.</content>
                        </paragraph>
                        <paragraph ID="p1412414341406734666">
                           <content styleCode="xmChange">To reduce the risk of
respiratory depression, proper dosing and titration of TARGINIQ ER
are essential <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2">2</linkHtml>)]</content>. Overestimating the TARGINIQ
ER dosage when converting patients from another opioid product can
result in a fatal overdose with the first dose.</content>
                        </paragraph>
                        <paragraph ID="p1412214341406734664">
                           <content styleCode="xmChange">Accidental ingestion of even one dose of TARGINIQ ER, especially
by children, can result in respiratory depression and death due to
an overdose of oxycodone.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="4525a5f1-ca4c-f265-6bc1-4d29d621943b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Neonatal Opioid Withdrawal Syndrome</title>
                     <text>
                        <paragraph ID="p1411834341406734662">
                           <content styleCode="xmChange">Prolonged use of TARGINIQ
ER during pregnancy can result in withdrawal in the neonate.  Neonatal
opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults,
may be life-threatening if not recognized and treated, and requires
management according to protocols developed by neonatology experts.
 Observe newborns for signs of neonatal opioid withdrawal syndrome
and manage accordingly. Advise pregnant women using opioids for a
prolonged period of the risk of neonatal opioid withdrawal syndrome
and ensure that appropriate treatment will be available <content styleCode="italics">[see
Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>),
Patient Counseling Information (<linkHtml href="#Section_17">17</linkHtml>)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="d455f8a0-dfc5-13c5-a656-41517c1d759c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Risks of Concomitant
Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers</title>
                     <text>
                        <paragraph ID="p1463444341406734957">
                           <content styleCode="xmChange">Concomitant
use of TARGINIQ ER with a CYP3A4 inhibitor, such as macrolide antibiotics
(e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole),
and protease inhibitors (e.g., ritonavir), may increase plasma concentrations
of oxycodone and prolong opioid adverse reactions, which may cause
potentially fatal respiratory depression <content styleCode="italics">[see Warnings and
Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>, particularly
when an inhibitor is added after a stable dose of TARGINIQ ER is achieved.
Similarly, discontinuation of a CYP3A4 inducer, such as rifampin,
carbamazepine, and phenytoin, in TARGINIQ ER-treated patients may
increase oxycodone plasma concentrations and prolong opioid adverse
reactions.  When using TARGINIQ ER with CYP3A4 inhibitors or discontinuing
CYP3A4 inducers in TARGINIQ ER-treated patients, monitor patients
closely at frequent intervals and consider dosage reduction of TARGINIQ
ER until stable drug effects are achieved <content styleCode="italics">[see Drug Interactions
(<linkHtml href="#Section_7">7</linkHtml>)].</content>
                           </content>
                        </paragraph>
                        <paragraph ID="p1462854341406734956">
                           <content styleCode="xmChange">Concomitant
use of TARGINIQ ER with CYP3A4 inducers or discontinuation of an CYP3A4
inhibitor could decrease oxycodone plasma concentrations, decrease
opioid efficacy or, possibly, lead to a withdrawal syndrome in a patient
who had developed physical dependence to oxycodone.  When using TARGINIQ
ER with CYP3A4 inducers or discontinuing CYP3A4 inhibitors, monitor
patients closely at frequent intervals and consider increasing the
opioid dosage if needed to maintain adequate analgesia or if symptoms
of opioid withdrawal occur <content styleCode="italics">[see Drug Interactions (<linkHtml href="#Section_7">7</linkHtml>)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="37a80500-1918-f46e-f1c7-7e060be55998"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Risks from Concomitant
Use with Benzodiazepines or Other CNS Depressants</title>
                     <text>
                        <paragraph ID="p4131134341406734995">
                           <content styleCode="xmChange">Profound
sedation, respiratory depression coma, and death may result from the
concomitant use of TARGINIQ ER with benzodiazepines or other CNS depressants
(e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers,
muscle relaxants, general anesthetics, antipsychotics, other opioids,
alcohol). Because of these risks, reserve concomitant prescribing
of these drugs for use in patients for whom alternative treatment
options are inadequate.</content>
                        </paragraph>
                        <paragraph ID="p7174351441480730080">
                           <content styleCode="xmChange">Observational studies
have demonstrated that concomitant use of opioid analgesics and benzodiazepines
increases the risk of drug-related mortality compared to use of opioid
analgesics alone.  Because of similar pharmacological properties,
it is reasonable to expect similar risk with the concomitant use of
other CNS depressant drugs with opioid analgesics <content styleCode="italics">[see Drug
Interactions (<linkHtml href="#Section_7">7</linkHtml>)]</content>.</content>
                        </paragraph>
                        <paragraph ID="p7172351441480730081">
                           <content styleCode="xmChange">If the decision is made to prescribe a benzodiazepine or other CNS
depressant concomitantly with an opioid analgesic, prescribe the lowest
effective dosages and minimum durations of concomitant use.  In patients
already receiving an opioid analgesic, prescribe a lower initial dose
of the benzodiazepine or other CNS depressant than indicated in the
absence of an opioid, and titrate based on clinical response. If an
opioid analgesic is initiated in a patient already taking a benzodiazepine
or other CNS depressant, prescribe a lower initial dose of the opioid
analgesic, and titrate based on clinical response. Follow patients
closely for signs and symptoms of respiratory depression and sedation.</content>
                        </paragraph>
                        <paragraph ID="p7170351441480730082">
                           <content styleCode="xmChange">Advise both patients and caregivers about the risks of respiratory
depression and sedation when TARGINIQ ER is used with benzodiazepines
or other CNS depressants (including alcohol and illicit drugs).  Advise
patients not to drive or operate heavy machinery until the effects
of concomitant use of the benzodiazepine or other CNS depressant have
been determined.  Screen patients for risk of substance use disorders,
including opioid abuse and misuse, and warn them of the risk for overdose
and death associated with the use of additional CNS depressants including
alcohol and illicit drugs <content styleCode="italics">[see Drug Interactions (<linkHtml href="#Section_7">7</linkHtml>), Patient Counseling Information (<linkHtml href="#Section_17">17</linkHtml>)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="bb8a2725-690f-f237-83d1-89e3f24ede5c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Risk of Life-Threatening
Respiratory Depression in Patients with Chronic Pulmonary Disease
or in Elderly, Cachectic, or Debilitated Patients</title>
                     <text>
                        <paragraph ID="p1486444341406735101">
                           <content styleCode="xmChange">The use of
TARGINIQ ER in patients with acute or severe bronchial asthma in an
unmonitored setting or in the absence of resuscitative equipment is
contraindicated.</content>
                        </paragraph>
                        <paragraph ID="p7190351441480730181">
                           <content styleCode="xmChange">
                              <content styleCode="underline">Patients with
Chronic Pulmonary Disease:</content> TARGINIQ ER-treated patients
with significant chronic obstructive pulmonary disease or cor pulmonale,
and those with a substantially decreased respiratory reserve, hypoxia,
hypercapnia, or pre-existing respiratory depression are at increased
risk of decreased respiratory drive including apnea, even at recommended
dosages of TARGINIQ ER <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)].</content>
                           </content>
                        </paragraph>
                        <paragraph ID="p7188351441480730182">
                           <content styleCode="xmChange">
                              <content styleCode="underline">Elderly, Cachectic, or Debilitated Patients:</content> Life-threatening
respiratory depression is more likely to occur in elderly, cachectic,
or debilitated patients because they may have altered pharmacokinetics
or altered clearance compared to younger, healthier patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)].</content>
                           </content>
                        </paragraph>
                        <paragraph ID="p7186351441480730184">
                           <content styleCode="xmChange">Monitor such patients
closely, particularly when initiating and titrating TARGIIQ ER and
when TARGINIQ ER is given concomitantly with other drugs that depress
respiration <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>, <linkHtml href="#Section_5.5">5.5</linkHtml>)]</content>.  Alternatively, consider the use of non-opioid analgesics
in these patients.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="7f8eddd9-58df-6bec-60a3-a9d5b7fdf566"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Adrenal Insufficiency</title>
                     <text>
                        <paragraph ID="p1486824341406735107">
                           <content styleCode="xmChange">Cases of
adrenal insufficiency have been reported with opioid use, more often
following greater than one month of use. Presentation of adrenal insufficiency
may include non-specific symptoms and signs including nausea, vomiting,
anorexia, fatigue, weakness, dizziness, and low blood pressure. If
adrenal insufficiency is suspected, confirm the diagnosis with diagnostic
testing as soon as possible. If adrenal insufficiency is diagnosed,
treat with physiologic replacement doses of corticosteroids. Wean
the patient off of the opioid to allow adrenal function to recover
and continue corticosteroid treatment until adrenal function recovers.
Other opioids may be tried as some cases reported use of a different
opioid without recurrence of adrenal insufficiency. The information
available does not identify any particular opioids as being more likely
to be associated with adrenal insufficiency.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.8">
                     <id root="3bba0c02-8a83-0540-a1bd-08d7e0dc283c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Severe Hypotension</title>
                     <text>
                        <paragraph ID="p1489124341406735233">
                           <content styleCode="xmChange">TARGINIQ
ER may cause severe hypotension, including orthostatic hypotension
and syncope in ambulatory patients.  There is an increased risk in
patients whose ability to maintain blood pressure has already been
compromised by a reduced blood volume or concurrent administration
of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics) <content styleCode="italics">[see Drug Interactions (<linkHtml href="#Section_7.1">7.1</linkHtml>)]</content>.  Monitor these patients for signs of hypotension after initiating
or titrating the dosage of TARGINIQ ER.  In patients with circulatory
shock, TARGINIQ ER may cause vasodilation that can further reduce
cardiac output and blood pressure.  Avoid the use of TARGINIQ ER in
patients with circulatory shock.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.9">
                     <id root="f653f5f3-f011-725b-8b3f-1b9f6c469c5d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Risks of Use in Patients
with Increased Intracranial Pressure, Brain Tumors, Head Injury or
Impaired Consciousness</title>
                     <text>
                        <paragraph ID="p1510844341406735261">
                           <content styleCode="xmChange">In patients who may be
susceptible to the intracranial effects of CO<sub>2</sub> retention (e.g., those with evidence of increased intracranial pressure
or brain tumors), TARGINIQ ER may reduce respiratory drive, and the
resultant CO<sub>2</sub> retention can further increase
intracranial pressure. Monitor such patients for signs of sedation
and respiratory depression, particularly when initiating therapy with
TARGINIQ ER.</content>
                        </paragraph>
                        <paragraph ID="p26916651441480730365">
                           <content styleCode="xmChange">Opioids may also obscure
the clinical course in a patient with a head injury. Avoid the use
of TARGINIQ ER in patients with impaired consciousness or coma.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.10">
                     <id root="c09f9937-7d06-9c13-3512-d6e9b1f0a9a4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Risks of Use in
Patients with Gastrointestinal Conditions</title>
                     <text>
                        <paragraph ID="p1511244341406735287">
                           <content styleCode="xmChange">TARGINIQ ER is contraindicated
in patients with known or suspected gastrointestinal obstruction,
including paralytic ileus.</content>
                        </paragraph>
                        <paragraph ID="p26910551441480730404">
                           <content styleCode="xmChange">The oxycodone in TARGINIQ
ER may cause spasm of the sphincter of Oddi. Opioids may cause increases
in the serum amylase. Monitor patients with biliary tract disease,
including acute pancreatitis, for worsening symptoms.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.11">
                     <id root="bd729965-4412-b814-6951-5dfee970e719"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Increased Risk of
Seizures in Patients with Seizure Disorders</title>
                     <text>
                        <paragraph ID="p1513624341406735313">
                           <content styleCode="xmChange">The oxycodone in TARGINIQ
ER may increase the frequency of seizures in patients with seizure
 disorders, and may increase the risk of seizures occurring in other
clinical settings associated with seizures.  Monitor patients with
a history of seizure disorders for worsened seizure control during
TARGINIQ ER therapy.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.12">
                     <id root="26027e55-b44f-feb6-0f95-b0568676f157"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Withdrawal</title>
                     <text>
                        <paragraph ID="p1512824341406735309">
                           <content styleCode="xmChange">Avoid the
use of mixed agonist/antagonist (e.g.., pentazocine, nalbuphine, and
butorphanol) or partial agonist (e.g., buprenorphine) analgesics in
patients who are receiving a full opioid agonist analgesic, including
TARGINIQ ER.  In these patients, mixed agonist/antagonist and partial
agonist analgesics may reduce the analgesic effect and/or may precipitate
withdrawal symptoms.</content>
                        </paragraph>
                        <paragraph ID="p7466951441480730453">
                           <content styleCode="xmChange">When discontinuing TARGINIQ
ER, gradually taper the dosage <content styleCode="italics">[see Dosage and Administration
(<linkHtml href="#Section_2.5">2.5</linkHtml>)]</content>.  Do not abruptly
discontinue TARGINIQ ER <content styleCode="italics">[see Drug Abuse and Dependence (<linkHtml href="#Section_9.3">9.3</linkHtml>)]</content>.</content>
                        </paragraph>
                        <paragraph ID="p271651551441480730455">
                           <content styleCode="xmChange">Symptoms
of opioid withdrawal occurred in some patients in clinical trials <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.1">6.1</linkHtml>)]. </content>Symptoms included but were not limited to hyperhidrosis, chills,
diarrhea, abdominal pain, anxiety, irritability, and yawning.  Monitor
patients for symptoms of opioid withdrawal.  In opioid-tolerant patients,
if symptoms of opioid withdrawal occur following conversion to TARGINIQ
ER or following dose escalation, consider lowering the dose to determine
whether symptoms are reduced.</content>
                        </paragraph>
                        <paragraph ID="p271791151441480730456">
                           <content styleCode="xmChange">Parenteral use of naloxone
has been associated with abrupt and complete reversal of opioid effects
leading to withdrawal symptoms (e.g., abdominal cramping, muscle aches,
sweating, anxiety, nausea, vomiting, diarrhea).  Several instances
of hypotension, hypertension, ventricular tachycardia and fibrillation,
and pulmonary edema have been associated with parenteral naloxone
used postoperatively.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.13">
                     <id root="b5aa77d6-0017-2e36-1ccb-4520abb97702"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Risks of Driving
and Operating Machinery</title>
                     <text>
                        <paragraph ID="p1512634341406735308">
                           <content styleCode="xmChange">TARGINIQ ER may impair
the mental or physical abilities needed to perform potentially hazardous
activities such as driving a car or operating machinery. Warn patients
not to drive or operate dangerous machinery unless they are tolerant
to the effects of TARGINIQ ER and know how they will react to the
medication <content styleCode="italics">[see Patient Counseling Information (<linkHtml href="#Section_17">17</linkHtml>)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.14">
                     <id root="9513af9a-1371-67d0-5a7c-cb38c3364287"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14 Laboratory Monitoring</title>
                     <text>
                        <paragraph ID="p1511644341406735298">
                           <content styleCode="xmChange">Not every urine drug
test for “opioids” or “opiates” detects oxycodone reliably, especially
those designed for in-office use.  Further, many laboratories will
report urine drug concentrations below a specified “cut-off” value
as “negative”.  Therefore, if urine testing for oxycodone is considered
in the clinical management of an individual patient, ensure that the
sensitivity and specificity of the assay is appropriate, and consider
the limitations of the testing used when interpreting results.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="94df3893-1f84-07a6-2207-083f3425efdd"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph ID="p1561624341406735545">The following serious adverse
reactions are described elsewhere in the labeling:</paragraph>
                  <br/>
                  <list listType="unordered" ID="l1562124341406735555" styleCode="Disc">
                     <item>Addiction, Abuse, and Misuse <content styleCode="italics">[see Warnings and Precautions
(<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>
                     </item>
                     <item>Life-Threatening Respiratory Depression <content styleCode="italics">[see Warnings
and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>
                     </item>
                     <item>Neonatal Opioid Withdrawal Syndrome <content styleCode="italics">[see Warnings
and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)]</content>
                     </item>
                     <item>Interactions with Benzodiazepine or Other CNS Depressants <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)]</content>
                     </item>
                     <item>Adrenal Insufficiency <content styleCode="italics">[see Warnings and Precautions
(<linkHtml href="#Section_5.7">5.7</linkHtml>)]</content>
                     </item>
                     <item>Severe Hypotension <content styleCode="italics">[see Warnings and Precautions
(<linkHtml href="#Section_5.8">5.8</linkHtml>)]</content>
                     </item>
                     <item>Gastrointestinal Adverse Reactions <content styleCode="italics">[see Warnings
and Precautions (<linkHtml href="#Section_5.10">5.10</linkHtml>)]</content>
                     </item>
                     <item>Seizures <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.11">5.11</linkHtml>]</content>
                     </item>
                     <item>Withdrawal <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.12">5.12</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20161222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph ID="p26071281406729291">Most common adverse reactions (incidence
≥ 5%) were nausea and vomiting. (<linkHtml href="#Section_6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph ID="p26093281406729293">
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Purdue Pharma L.P. at 1-888-726-7535 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="b1729422-7684-98f6-5254-f6defec770d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trial Experience</title>
                     <text>
                        <paragraph ID="p1641734341406736186">Because clinical trials are conducted under
widely varying conditions, adverse reaction rates observed in the
clinical trials of a drug cannot be directly compared to rates in
the clinical trials of another drug and may not reflect the rates
observed in practice.</paragraph>
                        <paragraph ID="p1641924341406736186">A total of 2,396 patients were treated in controlled and open-label
clinical studies with TARGINIQ ER.  Seven hundred and ninety-four
of these patients (33%) were treated for approximately six months
and 621 (26%) were treated for approximately one year.</paragraph>
                        <paragraph ID="p1642334341406736185">TARGINIQ ER may increase the
risk of serious adverse reactions such as those observed with other
opioid analgesics, including respiratory depression, apnea, respiratory
arrest, circulatory depression, hypotension, or shock <content styleCode="italics">[see
Overdosage (<linkHtml href="#Section_10">10</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p1642524341406736180">
                           <content styleCode="underline">Commonly Observed
Treatment-Emergent Adverse Reactions in a Clinical Study with TARGINIQ
ER in Opioid-Experienced Patients with Uncontrolled Moderate to Severe
Chronic Low Back Pain</content>
                           <br/>The safety data described
in Table 4 below are based on a 12-week, randomized, double-blind,
placebo-controlled clinical trial in opioid-experienced patients with
moderate to severe chronic low back pain.  This trial included 1,095
TARGINIQ ER-treated patients in an open-label titration period, and
298 TARGINIQ ER-and 302 placebo-treated patients in a double-blind
treatment period.  The mean age was 52 years old; 55% were female,
and 45% were male; 74% were Caucasian, 22% were Black, and 11% were
Hispanic.</paragraph>
                        <paragraph ID="p1642724341406736178">The most
common treatment-emergent adverse reactions (reported by ≥ 5% of TARGINIQ
ER subjects) during the open-label or double-blind periods were nausea
and vomiting.</paragraph>
                        <paragraph ID="p1641324341406736177">The
most common reason for discontinuation during the open-label period
due to treatment-emergent adverse reactions (reported by ≥ 1% of subjects)
was nausea (2%).</paragraph>
                        <paragraph ID="p1641544341406736176">The
most common reason for discontinuation during the double-blind period
due to treatment-emergent adverse reactions (reported by ≥ 1% of subjects
with TARGINIQ ER or placebo) was drug withdrawal syndrome (&lt;1%
vs. 1%), respectively.</paragraph>
                        <paragraph ID="p1642074341406736176">The incidence of treatment-emergent adverse reactions reported by
≥ 2% of subjects in a clinical trial comparing TARGINIQ ER with placebo
is shown in Table 4 below:</paragraph>
                        <table ID="t166458434" border="0" frame="void" rules="none" width="100%">
                           <caption>Table 4.  Incidence of Treatment-Emergent Adverse Reactions
Reported in &gt;2% of Subjects Taking TARGINIQ
ER: Safety Population (Open-Label Titration Period) and Randomized
Safety Population (Double-Blind Period)</caption>
                           <colgroup>
                              <col width="3%"/>
                              <col width="47%"/>
                              <col width="16%"/>
                              <col width="1%"/>
                              <col width="16%"/>
                              <col width="16%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="6">*Percentages in the table are based on <content styleCode="underline">adverse reaction reports</content> of Drug Withdrawal Syndrome
in the key efficacy and safety study. In addition to the adverse reaction
reports, an independent Adjudication Committee identified additional
subjects with possible drug withdrawal syndrome, resulting in a total
(adverse reactions plus adjudicated cases) of  2% of subjects in the
Open-Label Period, and in the Double-Blind Period 4% of subjects treated
with TARGINIQ ER and 2% treated with placebo.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Botrule" colspan="2"> </td>
                                 <td styleCode="Toprule Botrule Rrule" align="center">
                                    <content styleCode="bold">Open-Label Period</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule" align="center"> </td>
                                 <td styleCode="Toprule Botrule Lrule" colspan="2" align="center">
                                    <content styleCode="bold">Double-Blind
Period</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule" colspan="2"> </td>
                                 <td styleCode="Toprule Botrule Rrule" rowspan="4" align="center" valign="bottom">
                                    <content styleCode="bold">TARGINIQ</content>
                                    <br/>
                                    <content styleCode="bold">ER</content>
                                    <br/>
                                    <content styleCode="bold">(N=1095)</content>
                                    <br/>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                                 <td styleCode="Lrule Rrule" rowspan="13"> </td>
                                 <td styleCode="Toprule Botrule Lrule" rowspan="4" align="center" valign="bottom">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(N=302)</content>
                                    <br/>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                                 <td styleCode="Toprule Botrule" rowspan="4" align="center">
                                    <content styleCode="bold">TARGINIQ</content>
                                    <br/>
                                    <content styleCode="bold">ER</content>
                                    <br/>
                                    <content styleCode="bold">(N=298)</content>
                                    <br/>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2"> </td>
                              </tr>
                              <tr>
                                 <td colspan="2">
                                    <content styleCode="bold">MedDRA System Organ Class</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule"> </td>
                                 <td styleCode="Botrule">
                                    <content styleCode="bold">Preferred Term</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td>Nausea</td>
                                 <td align="center">7</td>
                                 <td align="center">5</td>
                                 <td align="center">8</td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td>Headache</td>
                                 <td align="center">4</td>
                                 <td align="center">3</td>
                                 <td align="center">3</td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td>Constipation</td>
                                 <td align="center">3</td>
                                 <td align="center">1</td>
                                 <td align="center">3</td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td>Abdominal pain</td>
                                 <td align="center">3</td>
                                 <td align="center">2</td>
                                 <td align="center">3</td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td>Vomiting</td>
                                 <td align="center">2</td>
                                 <td align="center">2</td>
                                 <td align="center">5</td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td>Pruritus</td>
                                 <td align="center">2</td>
                                 <td align="center">1</td>
                                 <td align="center">2</td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td>Anxiety</td>
                                 <td align="center">1</td>
                                 <td align="center">0</td>
                                 <td align="center">3</td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td>*Drug withdrawal syndrome</td>
                                 <td align="center">1</td>
                                 <td align="center">2</td>
                                 <td align="center">3</td>
                              </tr>
                              <tr>
                                 <td> </td>
                                 <td>Insomnia</td>
                                 <td align="center">1</td>
                                 <td align="center">1</td>
                                 <td align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule"> </td>
                                 <td styleCode="Botrule">Back pain</td>
                                 <td styleCode="Botrule" align="center">0</td>
                                 <td styleCode="Botrule Lrule Rrule"> </td>
                                 <td styleCode="Botrule" align="center">1</td>
                                 <td styleCode="Botrule" align="center">3</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p1641114341406736170">In a clinical trial,
the following adverse reactions were reported in patients treated
with TARGINIQ ER with an incidence between ≥ 1% and &lt;2%:</paragraph>
                        <paragraph ID="p1640914341406736169">
                           <content styleCode="italics">Eye disorders:</content>  lacrimation increased<br/>
                           <content styleCode="italics">General disorders and
administration site conditions:</content>  fatigue<br/>
                           <content styleCode="italics">Infections and infestations:</content>  influenza<br/>
                           <content styleCode="italics">Injury, poisoning, and procedural complications:</content>  fall<br/>
                           <content styleCode="italics">Musculoskeletal and connective tissue disorders:</content>  arthralgia<br/>
                           <content styleCode="italics">Nervous system disorders:</content>  dizziness, sinus headache, somnolence<br/>
                           <content styleCode="italics">Psychiatric
disorders:</content>  drug abuse<br/>
                           <content styleCode="italics">Skin and subcutaneous
tissue disorders:</content>  pruritus, rash, cold sweat<br/>
                           <content styleCode="italics">Vascular disorders:</content> hot flush, hypertension</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="61e1b954-c707-c57b-305a-477fbb33ff69"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph ID="p1640714341406736168">The following most frequently reported adverse
reactions have been identified during post-approval use of oxycodone/naloxone
extended-release tablets.  Because these reactions are reported voluntarily
from a population of uncertain size, it is not always possible to
reliably estimate their frequency or establish a causal relationship
to drug exposure.</paragraph>
                        <paragraph ID="p1845534341406737330">
                           <content styleCode="italics">Gastrointestinal Disorders:</content>  abdominal pain, constipation,
diarrhea, nausea, and vomiting</paragraph>
                        <paragraph ID="p1845334341406737330">
                           <content styleCode="italics">General Disorders and Administration
Site Conditions:</content> drug withdrawal syndrome, fatigue, pain,
malaise, and drug ineffective</paragraph>
                        <paragraph ID="p1845134341406737329">
                           <content styleCode="italics">Injury, Poisoning, and Procedural
Complications:</content> inadequate analgesia</paragraph>
                        <paragraph ID="p1844934341406737326">
                           <content styleCode="italics">Neoplasms Benign, Malignant, and
Unspecified (including cysts and polyps):</content> malignant neoplasm
progression</paragraph>
                        <paragraph ID="p1844734341406737324">
                           <content styleCode="italics">Nervous System Disorders:</content>  dizziness, headache, tremor,
and somnolence</paragraph>
                        <paragraph ID="p1844534341406737323">
                           <content styleCode="italics">Psychiatric Disorders:</content> restlessness, confusional state,
and anxiety</paragraph>
                        <paragraph ID="p1844334341406737320">
                           <content styleCode="italics">Respiratory, Thoracic, and Mediastinal Disorders:</content>  dyspnea</paragraph>
                        <paragraph ID="p1844134341406737318">
                           <content styleCode="italics">Skin and Subcutaneous
Tissue Disorders:</content>  hyperhidrosis and pruritus</paragraph>
                        <paragraph ID="p27927551441480731121">
                           <content styleCode="underline">Serotonin syndrome</content>: Cases of serotonin syndrome, a potentially life-threatening condition,
have been reported during concomitant use of opioids with serotonergic
drugs.</paragraph>
                        <paragraph ID="p10280951441480731123">
                           <content styleCode="underline">Adrenal insufficiency</content>: Cases of adrenal insufficiency
have been reported with opioid use, more often following greater than
one month of use.</paragraph>
                        <paragraph ID="p34605951441480731124">
                           <content styleCode="underline">Anaphylaxis</content>: Anaphylaxis has been reported
with ingredients contained in TARGINIQ ER.</paragraph>
                        <paragraph ID="p34608551441480731125">
                           <content styleCode="underline">Androgen deficiency</content>: Cases of androgen deficiency have occurred with chronic use of
opioids <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12.2">12.2</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="89a1c167-78e2-fece-3b76-26601252deb4"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph ID="p34837351441480731182">Table 5 includes clinically
significant drug interactions with TARGINIQ ER</paragraph>
                  <table ID="t3483945144" border="1" width="100%">
                     <caption>Table 5: Clinically Significant Drug Interactions with TARGINIQ
ER</caption>
                     <colgroup>
                        <col width="17*"/>
                        <col width="82*"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" colspan="2">
                              <content styleCode="bold">Inhibitors
of CYP3A4 and CYP2D6</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">The concomitant use of TARGINIQ
ER and CYP3A4 inhibitors can increase the plasma concentration of
oxycodone, resulting in increased or prolonged opioid effects. These
effects could be more pronounced with concomitant use of TARGINIQ
ER and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor
is added after a stable dose of TARGINIQ ER is achieved <content styleCode="italics">[see
Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)]</content>.<br/>After stopping a CYP3A4 inhibitor, as the effects of
the inhibitor decline, the oxycodone plasma concentration will decrease <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>, resulting in decreased opioid efficacy or a withdrawal
syndrome in patients who had developed physical dependence to oxycodone.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">If concomitant use is necessary,
consider dosage reduction of TARGINIQ ER until stable drug effects
are achieved. Monitor patients for respiratory depression and sedation
at frequent intervals.<br/>If a CYP3A4 inhibitor is discontinued,
consider increasing the TARGINIQ ER dosage until stable drug effects
are achieved.  Monitor for signs of opioid withdrawal.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Macrolide antibiotics (e.g.,
erythromycin), azole-antifungal agents (e.g. ketoconazole), protease
inhibitors (e.g., ritonavir)</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" colspan="2">
                              <content styleCode="bold">CYP3A4 Inducers</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">The concomitant use of TARGINIQ
ER and CYP3A4 inducers can decrease the plasma concentration of oxycodone <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>, resulting in decreased efficacy or onset of a withdrawal
syndrome in patients who have developed physical dependence to oxycodone <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.4">5.4</linkHtml>)]</content>.<br/>After stopping a CYP3A4 inducer, as the effects
of the inducer decline, the oxycodone plasma concentration will increase <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>, which could increase or prolong both the therapeutic
effects and adverse reactions, and may cause serious respiratory depression.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">If concomitant use is necessary,
consider increasing the TARGINIQ ER dosage until stable drug effects
are achieved. Monitor for signs of opioid withdrawal. If a CYP3A4
inducer is discontinued, consider TARGINIQ ER dosage reduction and
monitor for signs of respiratory depression.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Rifampin, carbamazepine, phenytoin</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" colspan="2">
                              <content styleCode="bold">Benzodiazepines
and Other Central Nervous System (CNS) Depressants</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Due to additive pharmacologic
effect, the concomitant use of benzodiazepines or other CNS depressants,
including alcohol, can increase the risk of hypotension, respiratory
depression, profound sedation, coma, and death.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Reserve concomitant prescribing
of these drugs for use in patients for whom alternative treatment
options are inadequate. Limit dosages and durations to the minimum
required. Follow patients closely for signs of respiratory depression
and sedation <content styleCode="italics">[see Dosage and Administration (2.4), Warnings
and Precautions(<linkHtml href="#Section_5.4">5.4</linkHtml>)]</content>.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Benzodiazepines and other sedatives/hypnotics,
anxiolytics, tranquilizers, muscle relaxants, general anesthetics,
, antipsychotics, other opioids, alcohol.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" colspan="2">
                              <content styleCode="bold">Serotonergic
Drugs</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">The concomitant use of opioids
with other drugs that affect the serotonergic neurotransmitter system
has resulted in serotonin syndrome.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">If concomitant use is warranted,
carefully observe the patient, particularly during treatment initiation
and dose adjustment.  Discontinue TARGINIQ ER if serotonin syndrome
is suspected.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Selective serotonin reuptake
inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors
(SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor
antagonists, drugs that affect the serotonin neurotransmitter system
(e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO)
inhibitors (those intended to treat psychiatric disorders and also
others, such as linezolid and intravenous methylene blue).</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" colspan="2">
                              <content styleCode="bold">Monoamine
Oxidase Inhibitors (MAOIs)</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">MAOI interactions with opioids
may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory
depression, coma) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)].</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">The use of TARGINIQ ER is not
recommended for patients taking MAOIs or within 14 days of stopping
such treatment.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">phenelzine, tranylcypromine,
linezolid</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" colspan="2">
                              <content styleCode="bold">Mixed Agonist/Antagonist
and Partial Agonist Opioid Analgesics</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">May reduce the analgesic effect
of TARGINIQ ER and/or precipitate withdrawal symptoms.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Avoid concomitant use.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Examples:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">butorphanol, nalbuphine, pentazocine,
buprenorphine</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" colspan="2">
                              <content styleCode="bold">Muscle Relaxants</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Oxycodone may enhance the neuromuscular
blocking action of skeletal muscle relaxants and produce an increased
degree of respiratory depression.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
respiratory depression that may be greater than otherwise expected
and decrease the dosage of TARGINIQ ER and/or the muscle relaxant
as necessary.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" colspan="2">
                              <content styleCode="bold">Diuretics</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Opioids can reduce the efficacy
of diuretics by inducing the release of antidiuretic hormone.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
diminished diuresis and/or effects on blood pressure and increase
the dosage of the diuretic as needed.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" colspan="2">
                              <content styleCode="bold">Anticholinergic
Drugs</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Clinical Impact:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">The concomitant use of anticholinergic
drugs may increase risk of urinary retention and/or severe constipation,
which may lead to paralytic ileus.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Rrule Lrule" align="right" valign="top">
                              <content styleCode="italics">Intervention:</content>
                           </td>
                           <td styleCode="Toprule Botrule Rrule Lrule">Monitor patients for signs of
urinary retention or reduced gastric motility when TARGINIQ ER is
used concomitantly with anticholinergic drugs.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20161222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l284014281406729411" styleCode="Disc">
                           <item>
                              <content styleCode="underline">CNS Depressants</content>: Concomitant use
may cause hypotension, profound sedation, respiratory depression,
coma, and death. If co-administration is require decision to begin
TARGINIQ ER is made, start with 1/3 to ½ the recommended starting
dosage, consider a dosage of the concommitant CNS depressant, and
monitor closely. (<linkHtml href="#Section_2.3">2.3</linkHtml>, <linkHtml href="#Section_5.5">5.5</linkHtml>, <linkHtml href="#Section_7">7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Serotonergic Drugs</content>: Concomitant use
may result in serotonin syndrome. Discontinue TARGINIQ ER if serotonin
syndrome is suspected. (<linkHtml href="#Section_7">7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Mixed Agonist/Antagonist and Partial Agonist
Opioid Analgesics</content>: Avoid use with TARGINIQ ER because
they may reduce analgesic effect of TARGINIQ ER or precipitate withdrawal
symptoms. (<linkHtml href="#Section_5.12">5.12</linkHtml>, <linkHtml href="#Section_7">7</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Monoamine Oxidase Inhibitors (MAOIs)</content>: Can potentiate the effects of morphine. Avoid concomitant use in
patients receiving MAOIs or within 14 days of stopping treatment with
an MAOI. (<linkHtml href="#Section_7">7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="8fe002b4-b4c5-247e-2fac-7c3f8b97944e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20161222"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" ID="l30811281406729440" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Pregnancy</content>: May cause fetal harm.
(<linkHtml href="#Section_8.1">8.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Lactation</content>: Not recommended. (<linkHtml href="#Section_8.2">8.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="84298fe9-77ae-1b9f-3979-d10718797a18"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph ID="p1924714341406737783">
                           <content styleCode="underline">Risk Summary</content>
                           <br/>Prolonged use of opioid analgesics during pregnancy may
cause neonatal opioid withdrawal <content styleCode="italics">[see Warnings and Precautions
(<linkHtml href="#Section_5.3">5.3</linkHtml>)]. </content>There are no adequate
and well-controlled studies with TARGINIQ ER in pregnant women. The
naloxone component of TARGINIQ ER may precipitate opioid withdrawal
in a fetus due to the immaturity of the fetal blood brain barrier.
 Animal reproduction studies were not conducted with the combination
of oxycodone and naloxone, the components of TARGINIQ ER.  However,
animal data are available from studies conducted with the individual
components.  Embryo-fetal toxicity was not observed following oral
administration of oxycodone to rats and rabbits during the period
of organogenesis at doses equal to or 30 times, respectively, the
maximum recommended daily dose (MRDD) of 80 mg oxycodone/day on a
body surface area basis. Decreased pup weight was observed in rats
with oral administration of oxycodone throughout pregnancy at doses
0.8 times the MRDD dose of 80 mg oxycodone/day.  Embryo-fetal toxicity
was not observed following oral administration of naloxone (800 mg/kg
or 400 mg/kg) to pregnant rats and rabbits, respectively, during organogenesis
at doses 192 times the MRDD of 40 mg naloxone/day, on a body surface
area basis.  In several published studies, treatment of pregnant rats
with oxycodone hydrochloride at clinically relevant doses and below
resulted in neurobehavioral effects in offspring <content styleCode="italics">[see Data].
 </content>Based on animal data, advise pregnant women of the potential
risk to a fetus.</paragraph>
                        <paragraph ID="p266731251441480733950">The estimated background risk of major birth defects and miscarriage
for the indicated population is unknown.  All pregnancies have a background
risk of birth defect, loss, or other adverse outcomes.  In the U.S.
general population, the estimated background risk of major birth defects
and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%,
respectively.</paragraph>
                        <paragraph ID="p1924514341406737782">
                           <content styleCode="underline">Clinical Considerations</content>
                           <br/>
                           <content styleCode="italics">Fetal/neonatal
adverse reactions</content>
                           <br/>Prolonged use of opioid analgesics
during pregnancy for medical or nonmedical purposes can result in
physical dependence in the neonate and neonatal opioid withdrawal
syndrome shortly after birth.</paragraph>
                        <paragraph ID="p11533351441480733972">Neonatal opioid withdrawal syndrome presents
as irritability, hyperactivity and abnormal sleep pattern, high pitched
cry, tremor, vomiting, diarrhea, and failure to gain weight. The onset,
duration, and severity of neonatal opioid withdrawal syndrome vary
based on the specific opioid used, duration of use, timing and amount
of last maternal use, and rate of elimination of the drug by the newborn.
Observe newborns for symptoms of neonatal opioid withdrawal syndrome
and manage accordingly <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.3">5.3</linkHtml>)].</content>
                        </paragraph>
                        <paragraph ID="p284561451441480734005">
                           <content styleCode="italics">Labor or Delivery</content>
                        </paragraph>
                        <paragraph ID="p284431351441480734019">Opioids cross the placenta
and may produce respiratory depression and psycho-physiologic effects
in neonates.  An opioid antagonist, such as naloxone, must be available
for reversal of narcotic-opioid induced respiratory depression in
the neonate. TARGINIQ ER is not recommended for use in women during
or immediately prior to labor, when use of shorter acting analgesics
or other analgesic techniques are more appropriate.  Opioid analgesics,
including TARGINIQ ER, can prolong labor through actions which temporarily
reduce the strength, duration, and frequency of uterine contractions.
 However, this effect is not consistent and may be offset by an increased
rate of cervical dilation, which tends to shorten labor.  Monitor
neonates exposed to opioid analgesics during labor for signs of excess
sedation and respiratory depression.</paragraph>
                        <paragraph ID="p284621351441480734031">
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph ID="p284491351441480734044">
                           <content styleCode="italics">Animal Data</content>
                           <br/>There are no studies examining the reproductive and developmental
effects of the combination of oxycodone and naloxone; however, there
are data with the individual agents.</paragraph>
                        <paragraph ID="p284161551441480734056">Oxycodone</paragraph>
                        <paragraph ID="p284291251441480734064">Studies with oral doses of oxycodone hydrochloride
in rats up to 8 mg/kg/day and rabbits up to 125 mg/kg/day, equivalent
to 1 and 30 times the maximum total daily dose of 80 mg oxycodone/day,
respectively on a mg/m<sup>2</sup> basis, did not
reveal evidence of harm to the fetus due to oxycodone.  In a pre-
and postnatal toxicity study, female rats received oxycodone during
gestation and lactation.  There were no long-term developmental or
reproductive effects in the pups.</paragraph>
                        <paragraph ID="p284331251441480734080">Oxycodone hydrochloride was administered
orally to female rats during gestation and lactation in a pre- and
postnatal toxicity study.  There were no drug-related effects on reproductive
performance in these females or any long-term developmental or reproductive
effects in pups born to these rats.  Decreased body weight was found
during lactation and the early post-weaning phase in pups nursed by
mothers given the highest dose used (6 mg/kg/day, equivalent to approximately
0.8-times the maximum total daily dose of 80 mg/day, on a mg/m<sup>2</sup> basis).  However, body weight of these pups recovered.</paragraph>
                        <paragraph ID="p27171351441480734081">In published studies, offspring
of pregnant rats administered oxycodone hydrochloride during gestation
have been reported to exhibit neurobehavioral effects including altered
stress responses and increased anxiety-like behavior (2 mg/kg/day
IV from Gestation Day 8 to 21 and Postnatal Day 1, 3, and 5; 0.3 times
an adult human oral dose of 60 mg/day on a mg/m<sup>2</sup> basis), and altered learning and memory (15 mg/kg/day orally from
breeding through parturition; 2.4 times an adult human oral dose of
60 mg/day on a mg/m<sup>2</sup> basis).</paragraph>
                        <paragraph ID="p281991551441480734105">Naloxone</paragraph>
                        <paragraph ID="p28196051441480734107">Orally administered naloxone was not teratogenic
in the rat or rabbit at the maximum dosages tested (800 mg/kg/day
or 400 mg/kg/day, respectively) which were equivalent to approximately
192-times the intake of naloxone at the maximum recommended dose of
40 mg naloxone/day on a mg/m<sup>2</sup> basis.</paragraph>
                        <paragraph ID="p28161151441480734113">In a peri-/post-natal development
study with naloxone in rats, the highest dosage of 800 mg/kg/day (192-times
the intake of naloxone at the maximum total daily dose of 40 mg naloxone/day,
on a mg/m<sup>2</sup> basis) produced mortality and
significant toxicity in maternal rats, which was associated with increased
pup deaths in the immediate postpartum period.  Mild toxic signs were
also observed in maternal rats that received 200 mg/kg/day (approximately
48-times the intake of naloxone at the maximum daily dose of 40 mg
naloxone on a body surface area basis); however, there were no adverse
effects on the pups.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="4b9100c5-8a8b-f47e-34ba-4b3b1cc189f7"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph ID="p1924314341406737781">
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph ID="p1924114341406737779">Oxycodone is present
in breast milk. Published lactation studies report variable concentrations
of oxycodone in breast milk with administration of immediate-release
oxycodone to nursing mothers in the early postpartum period. The lactation
studies did not assess breastfed infants for potential adverse reactions.
Lactation studies have not been conducted with TARGINIQ ER.  It is
unknown whether naloxone is present in breast milk.  Instruct patients
not to undertake nursing while receiving TARGINIQ ER.  Because of
the potential for serious adverse reactions, including excess sedation
and respiratory depression in a breastfed infant, advise patients
that breastfeeding is not recommended during treatment with TARGINIQ
ER.</paragraph>
                        <paragraph ID="p1923914341406737777">
                           <content styleCode="underline">Clinical
Considerations</content>
                           <br/>Infants exposed to TARGINIQ
ER through breast milk should be monitored for excess sedation and
respiratory depression.  Withdrawal symptoms can occur in breast-fed
infants when maternal administration of an opioid analgesic is stopped,
or when breast-feeding is stopped. Furthermore, naloxone may precipitate
opioid withdrawal in a breast-fed infant.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.3">
                     <id root="9bde81b0-e616-9da6-0cdc-1fa353e92bf9"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph ID="p1922714341406737765">
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph ID="p1922514341406737764">Chronic use of opioids
may cause reduced fertility in females and males of reproductive potential.
It is not known whether these effects on fertility are reversible <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.2">6.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="c8933a1a-b44d-a5e4-7d0b-ffd58b44400f"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph ID="p1922314341406737758">Safety and effectiveness of TARGINIQ ER
in pediatric patients below the age of 18 years have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20140731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="ceb1b8df-7b23-8efe-9180-814ea4d16ef2"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph ID="p1921924341406737756">A prospective study conducted in two age
groups (younger: 19-44 years old vs. elderly: 65-77 years old) to
assess age effects on the PK of TARGINIQ ER (10 mg/5 mg) demonstrated
slightly higher steady-state oxycodone AUC (18% increase), and higher
steady-state naloxone AUC (82% increase) for elderly subjects compared
with younger subjects.  Evaluate elderly patients at frequent intervals
and consider TARGINIQ ER dose adjustments until stable drug effects
are achieved.</paragraph>
                        <paragraph ID="p291901251441480734325">Respiratory
depression is the chief risk for elderly patients treated with opioids,
and has occurred after large initial doses were administered to patients
who were not opioid-tolerant or when opioids were co-administered
with other agents that depress respiration. Titrate the dosage of
TARGINIQ ER slowly in geriatric patients and monitor closely for signs
of central nervous system and respiratory depression <content styleCode="italics">[see
Warnings and Precautions (<linkHtml href="#Section_5.6">5.6</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p11562351441480734352">Oxycodone and
naloxone are known to be substantially excreted by the kidney, and
the risk of adverse reactions to this drug may be greater in patients
with impaired renal function. Because elderly patients are more likely
to have decreased renal function, care should be taken in dose selection,
and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="9f87ad2c-1695-1ad0-a331-e3a119f87c3c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph ID="p1975774341406738101">A clinical trial has shown that plasma concentrations
of both oxycodone and naloxone are elevated in patients with hepatic
impairment.  Naloxone concentrations were affected to a higher degree
than oxycodone. When administering TARGINIQ ER to patients with mild
hepatic impairment, a dosage adjustment is recommended <content styleCode="italics">[see
Dosage and Administration (<linkHtml href="#Section_2.4">2.4</linkHtml>)].</content> Monitor patients closely for signs of central nervous system or
respiratory depression due to elevated levels of oxycodone and for
signs of withdrawal due to elevated levels of naloxone.  TARGINIQ
ER is contraindicated in patients with moderate and severe hepatic
impairment<content styleCode="italics"> [see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.7">
                     <id root="263ec355-c703-8f35-0437-a4fa191ca7a1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph ID="p1997634341406738127">A clinical trial has shown that plasma concentrations
of both oxycodone and naloxone are elevated in patients with renal
impairment. Naloxone concentrations were affected to a higher degree
than oxycodone. When administering TARGINIQ ER to patients with renal
impairment, a dosage reduction is recommended <content styleCode="italics">[see Dosage
and Administration (<linkHtml href="#Section_2.5">2.5</linkHtml>)].</content> Monitor patients closely for signs of central nervous system or
respiratory depression due to elevated levels of oxycodone and for
signs of withdrawal due to elevated levels of naloxone. As patients
with severe renal impairment may be at greater risk for opioid withdrawal-related
adverse events, consider using alternative products without naloxone <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#Section_12.3">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_9">
               <id root="3cecd394-766e-4f2f-764a-f8d73f9b2f7a"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20161222"/>
               <component>
                  <section ID="Section_9.1">
                     <id root="401f61f4-9dc5-1769-2a72-48d07e73b2e0"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph ID="p1999324341406738166">TARGINIQ ER contains oxycodone,
a Schedule II controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_9.2">
                     <id root="47b50728-2709-db78-11d1-6814f0588640"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph ID="p2024214341406738218">TARGINIQ ER contains oxycodone, a substance with a high potential
for abuse similar to other opioids including fentanyl, hydrocodone,
hydromorphone, methadone, morphine, oxymorphone, and tapentadol. 
TARGINIQ ER can be abused and is subject to misuse, addiction, and
criminal diversion <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p2024014341406738217">The high drug content in extended-release
formulations adds to the risk of adverse outcomes from abuse and misuse.</paragraph>
                        <paragraph ID="p2023814341406738215">All patients treated with opioids
require careful monitoring for signs of abuse and addiction, because
use of opioid analgesic products carries the risk of addiction even
under appropriate medical use.</paragraph>
                        <paragraph ID="p2023614341406738212">Prescription drug abuse is the intentional
non-therapeutic use of a prescription drug, even once, for its rewarding
psychological or physiological effects.</paragraph>
                        <paragraph ID="p2023414341406738211">Drug addiction is a cluster of behavioral,
cognitive, and physiological phenomena that develop after repeated
substance use and includes: a strong desire to take the drug, difficulties
in controlling its use, persisting in its use despite harmful consequences,
a higher priority given to drug use than to other activities and obligations,
increased tolerance, and sometimes a physical withdrawal.</paragraph>
                        <paragraph ID="p2023214341406738209">"Drug-seeking" behavior is very
common in persons with substance use disorders.  Drug-seeking tactics
include emergency calls or visits near the end of office hours, refusal
to undergo appropriate examination, testing, or referral, repeated
“loss” of prescriptions, tampering with prescriptions and reluctance
to provide prior medical records or contact information for other
healthcare provider(s).  “Doctor shopping” (visiting multiple prescribers
to obtain additional prescriptions) is common among drug abusers and
people suffering from untreated addiction.  Preoccupation with achieving
adequate pain relief can be appropriate behavior in a patient with
poor pain control.</paragraph>
                        <paragraph ID="p2023014341406738208">Abuse and addiction are separate and distinct from physical dependence
and tolerance.  Healthcare providers should be aware that addiction
may not be accompanied by concurrent tolerance and symptoms of physical
dependence in all addicts.  In addition, abuse of opioids can occur
in the absence of true addiction.</paragraph>
                        <paragraph ID="p12311551441480734552">TARGINIQ ER, like other opioids, can be
diverted for non-medical use into illicit channels of distribution.
 Careful record-keeping of prescribing information, including quantity,
frequency, and renewal requests, as required by state and federal
law, is strongly advised.</paragraph>
                        <paragraph ID="p282091251441480734556">Proper assessment of the patient, proper
prescribing practices, periodic reevaluation of therapy, and proper
dispensing and storage are appropriate measures that help to limit
abuse of opioid drugs.</paragraph>
                        <paragraph ID="p2022814341406738207">
                           <content styleCode="italics">
                              <content styleCode="underline">Risks Specific to Abuse of TARGINIQ ER</content>
                           </content>
                           <br/>TARGINIQ ER is for oral use only.  Abuse of
TARGINIQ ER poses a risk of overdose and death.  The risk is increased
with concurrent use of TARGINIQ ER with alcohol and other central
nervous system depressants.  Taking cut, broken, chewed, crushed,
or dissolved TARGINIQ ER enhances drug release and increases the risk
of overdose and death.</paragraph>
                        <paragraph ID="p2022614341406738206">If TARGINIQ ER tablets are crushed and administered via intranasal
or intravenous routes, the resulting systemic naloxone concentrations
are much higher and can induce a severe withdrawal syndrome in opioid-dependent
individuals. Cases have been reported to the international drug safety
database that involved attempts to manipulate the product for injection
or insufflation, which resulted in withdrawal symptoms.  In the majority
of these cases, emergency attention was required.</paragraph>
                        <paragraph ID="p2022414341406738205">With parenteral abuse, the inactive ingredients
in TARGINIQ ER can be expected to result in local tissue necrosis,
infection, pulmonary granulomas, and increased risk of endocarditis
and valvular heart injury.  Parenteral drug abuse is commonly associated
with transmission of infectious diseases, such as hepatitis and HIV.</paragraph>
                        <paragraph ID="p2000824341406738199">
                           <content styleCode="underline">Abuse Deterrence
Studies</content>
                        </paragraph>
                        <paragraph ID="p12577351441480734634">
                           <content styleCode="italics">In Vitro Testing</content>
                        </paragraph>
                        <paragraph ID="p12575351441480734636">In vitro physical and chemical tablet manipulation
studies were performed to evaluate the success of different extraction
methods in defeating the controlled-release formulation of TARGINIQ
ER and separating the oxycodone component from naloxone, a potent
opioid antagonist.  Laboratory test data demonstrate that TARGINIQ
ER can be crushed and dissolved in solution.  However, complete separation
or complete inactivation of naloxone from oxycodone was not achieved
despite using various techniques and conditions.</paragraph>
                        <paragraph ID="p12573351441480734637">
                           <content styleCode="italics">Clinical Abuse Potential Studies</content>
                        </paragraph>
                        <paragraph ID="p12566451441480734638">In the clinical
abuse potential studies described below, drug-liking was measured
on a bipolar drug liking scale of 0 to 100 where 50 represents a neutral
response of neither liking nor disliking, 0 represents maximum disliking
and 100 represents maximum liking. Response to whether the subject
would take the study drug again was measured on a unipolar scale of
0 to 100 where 0 represents the strongest negative response (“definitely
would not take drug again”) and 100 represents the strongest positive
response (“definitely would take drug again”). Response to subjective
feeling of getting “high” was measured on a unipolar scale of 0 to
100, where 0 represents “definitely not” and 100 represents “definitely
so”.</paragraph>
                        <paragraph ID="p12568851441480734670">
                           <content styleCode="italics">Study
in Non-Dependent, Opioid Abusers (Intranasal (IN) Administration)</content>
                        </paragraph>
                        <paragraph ID="p12550351441480734672">In a randomized,
double-blind, placebo- and active-controlled, 3-period crossover pharmacodynamic
study, 23 non-dependent,  opioid abusers with moderate experience
with opioids received IN administered TARGINIQ ER 40 mg/20 mg (finely
crushed tablets), oxycodone HCl 40 mg powder (active control), and
placebo treatments.</paragraph>
                        <paragraph ID="p12548351441480734674">IN administration of finely crushed TARGINIQ ER was associated with
statistically significant lower maximum drug liking scores (<content styleCode="italics">p</content> &lt; 0.001) and statistically significant lower maximum
scores for take drug again (<content styleCode="italics">p</content> &lt; 0.001), compared
to powdered oxycodone HCl, and was associated with similar mean and
median maximum scores for drug liking and take drug again, compared
to placebo treatment, as summarized in Table 6.</paragraph>
                        <table ID="t204907434" border="0" frame="void" rules="none" width="100%">
                           <caption>Table 6.  Summary of Maximum Drug Liking (E<sub>max</sub>) and Take Drug Again (E<sub>max</sub>) Following Intranasal
(IN) Administration of TARGINIQ ER, Oxycodone, and Placebo in Non-Dependent,
Opioid Abusers (N=23)</caption>
                           <colgroup>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="5">VAS: visual analog scale</td>
                              </tr>
                              <tr>
                                 <td colspan="5">SE: standard error</td>
                              </tr>
                              <tr>
                                 <td colspan="5">* Drug Liking Question text:  “At this moment, my
liking for this drug is”; scale: 0 = maximum disliking, 50 = neither
liking nor disliking (neutral response), 100 = maximum liking.</td>
                              </tr>
                              <tr>
                                 <td colspan="5">**Take Drug Again Question text:  “I would take this
drug again”; scale:  0 = definitely not, 100 = definitely so.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Lrule Rrule">VAS</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule"> </td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">TARGINIQ ER 40 mg/20 mg<br/>(finely crushed)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Oxycodone HCl 40 mg<br/>(powdered)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Placebo<br/>(lactose
powder)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule" rowspan="2" valign="top">Drug
Liking*</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Mean (SE)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">59.1 (2.8)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">94.8 (2.2)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">53.2 (2.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Median (Range)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">51 (50-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">100 (61-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">51 (50-100)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule" rowspan="2" valign="top">Take
Drug Again**</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Mean (SE)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">42.6 (6.4)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">93.6 (2.3)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">30.7 (6.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Median (Range)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">50.0 (0-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">100 (62-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">50 (0-100)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p2000434341406738197">Figure 1 demonstrates
a comparison of maximum drug liking for finely crushed TARGINIQ ER
compared to powdered oxycodone HCl in subjects who received both treatments.
 The Y-axis represents the percent of subjects attaining a percent
reduction in maximum drug liking for TARGINIQ ER vs. oxycodone HCl
powder greater than or equal to the value on the X-axis. Among non-dependent,
opioid drug abusers, 78% (n = 18) of subjects had a reduction of at
least 30% in maximum drug liking with TARGINIQ ER compared to oxycodone
HCl, and approximately 74% (n = 17) of subjects had a reduction of
at least 50% in maximum drug liking with TARGINIQ ER compared to oxycodone
HCl.</paragraph>
                        <paragraph ID="p2124844341406738724">
                           <content styleCode="bold">Figure
1. Percent Reduction in Maximum Drug Liking for Finely Crushed TARGINIQ
ER 40 mg/20 mg vs. Powdered Oxycodone HCl 40 mg Following Intranasal
Administration in Non-Dependent Opioid Abusers</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="g13338351441480734841"/>
                        <paragraph ID="p2124954341406738740">
                           <content styleCode="italics">Study in Non-Dependent, Opioid Abusers
(Intravenous (IV) Administration)</content>
                           <br/>In a randomized,
double-blind, placebo- and active-controlled, 3-period crossover pharmacodynamic
study, 22 non-dependent, opioid abusers with moderate experience with
opioids received intravenously administered 0.07 mg/kg oxycodone HCl
and 0.035 mg/kg naloxone HCl solution (simulated version of TARGINIQ
ER), oxycodone HCl (0.07 mg/kg solution; active control) and placebo
(saline) treatments.</paragraph>
                        <paragraph ID="p2129174341406738766">The intravenous administration of simulated TARGINIQ ER solution
was associated with statistically significant lower maximum drug liking
scores (<content styleCode="italics">p</content> &lt; 0.001) and statistically significant
lower maximum scores for take drug again (<content styleCode="italics">p</content> &lt;
0.001), compared to oxycodone solution, and was associated with similar
mean and median scores for drug liking and take drug again, compared
to placebo treatment, as summarized in Table 7.</paragraph>
                        <table ID="t59114434" border="0" frame="void" rules="none" width="100%">
                           <caption>Table 7.  Summary of Maximum Drug Liking (E<sub>max</sub>) and Take Drug Again Following IV Administration of Oxycodone HCl
+ Naloxone HCl (Simulated TARGINIQ ER Solution), Oxycodone HCl, and
Placebo in Non-Dependent, Opioid Abusers (N=22)</caption>
                           <colgroup>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                              <col width="20%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="5">VAS: visual analog scale</td>
                              </tr>
                              <tr>
                                 <td colspan="5">SE: standard error</td>
                              </tr>
                              <tr>
                                 <td colspan="5">* Drug Liking Question text:  “At this moment, my
liking for this drug is”; scale: 0 = maximum disliking, 50 = neither
liking nor disliking (neutral response), 100 = maximum liking.</td>
                              </tr>
                              <tr>
                                 <td colspan="5">**Take Drug Again Question text:  “I would take this
drug again”; scale:  0 = definitely not, 100 = definitely so; Values
obtained at 8 hours post dose.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Lrule Rrule">VAS</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule"> </td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Oxycodone HCl/<br/>Naloxone
HCl<br/>0.07/0.35 mg/kg</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Oxycodone HCl<br/>0.07
mg/kg</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Placebo<br/>saline (0.9%
NaCl)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule" rowspan="2" valign="top">Drug
Liking*</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Mean (SE)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">56.5 (2.8)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">96.4 (2.3)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">48.7 (2.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Median (Range)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">51 (50-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">100 (50-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">51.0 (0-53)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule" rowspan="2" valign="top">Take
Drug Again**</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Mean (SE)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">37.0 (6.2)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">82.0 (6.0)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">34.5 (5.1))</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Median (Range)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">50.0 (0-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">99.0 (0-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">50.0 (0-55)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p2127944341406738762">Figure 2 demonstrates
a comparison of maximum drug liking for simulated TARGINIQ ER solution
compared to oxycodone HCl solution in subjects who received both treatments.
Among non-dependent, opioid drug abusers, approximately 91% (n = 20)
of subjects had a reduction of at least 50% in maximum drug liking
with TARGINIQ ER compared to oxycodone solution.</paragraph>
                        <paragraph ID="p2127744341406738761">
                           <content styleCode="bold">Figure 2. Percent Reduction in Maximum
Drug Liking for Oxycodone 0.07 mg/kg + Naloxone 0.035 mg/kg (Simulated
TARGINIQ ER) vs. Oxycodone HCl 0.07 mg/kg Following Intravenous Administration
in Non-Dependent, Opioid Abusers</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="g14110351441480735015"/>
                        <paragraph ID="p2127544341406738759">
                           <content styleCode="italics">Study in Opioid-Dependent Subjects</content>
                           <br/>In a randomized, double-blind, placebo- and positive-controlled,
4-period crossover pharmacodynamic study, 29 opioid-dependent, methadone-maintained
subjects received orally administered TARGINIQ ER 60 mg/30 mg chewed
and intact tablets, oxycodone HCl solution 60 mg (active control)
and placebo (chewed and intact tablets and solution) treatments.</paragraph>
                        <paragraph ID="p2127344341406738759">The oral administration of TARGINIQ
ER, either chewed or intact, was associated with statistically significant
lower maximum drug liking scores (<content styleCode="italics">p</content> &lt; 0.001) and
statistically significant lower scores for take drug again (<content styleCode="italics">p</content> &lt; 0.001), compared to oxycodone solution, and was associated
with similar mean and median maximum scores for drug liking and take
drug again, compared to placebo treatment, as summarized in Table
8.</paragraph>
                        <table ID="t217948434" border="0" frame="void" rules="none" width="100%">
                           <caption>Table 8.  Summary of High, Maximum Drug Liking (E<sub>max</sub>), and Take Drug Again Following Oral Administration
of TARGINIQ ER (Intact and Chewed), Oxycodone HCl solution, and Placebo
in Opioid-Dependent Subjects (N=29)</caption>
                           <colgroup>
                              <col width="18%"/>
                              <col width="18%"/>
                              <col width="16%"/>
                              <col width="16%"/>
                              <col width="16%"/>
                              <col width="16%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="6">VAS: visual analog scale</td>
                              </tr>
                              <tr>
                                 <td colspan="6">SE: standard error</td>
                              </tr>
                              <tr>
                                 <td colspan="6">* Drug Liking Question text:  “At this moment, my
liking for this drug is”; scale: 0 = maximum disliking, 50 = neither
liking nor disliking (neutral response), 100 = maximum liking.</td>
                              </tr>
                              <tr>
                                 <td colspan="6">**Take Drug Again Question text:  “I would take this
drug again”; scale:  0 = definitely not, 100 = definitely so; Values
obtained at 12 hours post dose.</td>
                              </tr>
                              <tr>
                                 <td colspan="6">***Getting High Question Text:  “I am feeling high”;
scale: 0 = definitely not, 100 = definitely so.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr valign="top">
                                 <td styleCode="Toprule Botrule Lrule Rrule">VAS</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule"> </td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">TARGINIQ ER<br/>60 mg/30
mg intact </td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">TARGINIQ ER<br/>60 mg/30
mg chewed</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Oxycodone HCl<br/>solution
60 mg</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Placebo<br/>chewed and
intact tablet, solution</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule" rowspan="2" valign="top">Drug
Liking*</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Mean (SE)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">54.7 (2.0)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">54.6 (3.2)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">77.9 (3.8)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">54.4 (2.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Median (Range)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">51.0 (50-99)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">51.0 (0-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">78.0 (50-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">51.0 (50-100)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule" rowspan="2" valign="top">Take
Drug Again**</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Mean (SE)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">38.5 (5.7)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">32.6 (5.9)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">61.4 (5.9)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">41.5 (5.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Median (Range)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">50.0 (0-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">50.0 (0-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">50.0 (0-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">50.0 (0-100)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule" rowspan="2" valign="top">Getting
High***</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Mean (SE)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">20.6 (5.1)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">27.7 (6.5)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">77.9 (5.0)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">20.6 (5.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Botrule Lrule Rrule">Median (Range)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">1.0 (0-73)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">1.0 (0-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">86.0 (0-100)</td>
                                 <td styleCode="Toprule Botrule Lrule Rrule">1.0 (0-82)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p2127154341406738757">Figure 3 demonstrates
a comparison of maximum drug liking (E<sub>max</sub>)
for TARGINIQ ER either chewed or intact compared to oxycodone solution
in subjects who received both treatments. Among opioid-dependent subjects,
69.0% (n = 20)  had a reduction of at least 30%,  and 65.5% (n = 19)
of subjects had a reduction of at least 50% in maximum drug liking
with chewed TARGINIQ ER tablets compared to oxycodone solution; 79.3%
(n = 23) of subjects had a reduction at least 50% in maximum drug
liking with intact TARGINIQ ER tablets compared to oxycodone solution.</paragraph>
                        <paragraph ID="p2126944341406738751">
                           <content styleCode="bold">Figure 3. Percent Reduction
in Maximum Drug Liking for TARGINIQ ER 60 mg/30 mg Chewed or Intact
vs. Oxycodone HCl 60 mg Solution Following Oral Administration in
Opioid-Dependent Subjects</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="g15150351441480735198"/>
                        <paragraph ID="p2126744341406738750">
                           <content styleCode="italics">
                              <content styleCode="underline">Summary</content>
                           </content>
                           <br/>Based on the in vitro study results, it is expected that
abuse of oxycodone from physically and chemically manipulated TARGINIQ
ER tablets will be deterred by the inability to separate the two active
components.</paragraph>
                        <paragraph ID="p2126544341406738749">The data
from the clinical abuse potential studies indicate that TARGINIQ ER
has pharmacologic properties that are expected to reduce abuse via
the intranasal and intravenous routes of administration.  However,
abuse of TARGINIQ ER by these routes is still possible.</paragraph>
                        <paragraph ID="p2126344341406738748">Additional data, including epidemiological
data, when available, may provide further information on the impact
of TARGINIQ ER on the abuse liability of the drug in the community.
 Accordingly, this section may be updated in the future as appropriate.</paragraph>
                        <paragraph ID="p2126144341406738746">TARGINIQ ER contains oxycodone,
an opioid agonist and Schedule II controlled substance with an abuse
liability similar to other opioid agonists, legal or illicit, including
fentanyl, hydromorphone, methadone, morphine, and oxymorphone. TARGINIQ
ER can be abused and is subject to misuse, addiction, and criminal
diversion <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>), and Drug Abuse and Dependence (<linkHtml href="#Section_9.1">9.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                     <component>
                        <observationMedia ID="g13338351441480734841">
                           <text>figure-1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-1.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="g14110351441480735015">
                           <text>figure-2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="g15150351441480735198">
                           <text>figure-3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="figure-3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_9.3">
                     <id root="1d01e320-c84c-f901-f254-c00b6fb8c257"/>
                     <code code="34087-7" codeSystem="2.16.840.1.113883.6.1" displayName="DEPENDENCE SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph ID="p2125944341406738745">Both tolerance and physical dependence can develop during chronic
opioid therapy.  Tolerance is the need for increasing doses of opioids
to maintain a defined effect such as analgesia (in the absence of
disease progression or other external factors).  Tolerance may occur
to both the desired and undesired effects of drugs, and may develop
at different rates for different effects.</paragraph>
                        <paragraph ID="p2125744341406738744">Physical dependence results in withdrawal
symptoms after abrupt discontinuation or a significant dosage reduction
of a drug.  Withdrawal also may be precipitated through the administration
of drugs with opioid antagonist activity (e.g., naloxone, nalmefene),
mixed agonist/antagonist analgesics (e.g., pentazocine, butorphanol,
nalbuphine), or partial agonists (e.g., buprenorphine).  Physical
dependence may not occur to a clinically significant degree until
after several days to weeks of continued opioid usage.</paragraph>
                        <paragraph ID="p2125544341406738742">TARGINIQ ER should not be abruptly
discontinued <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.7">2.7</linkHtml>)]</content>.  If TARGINIQ ER is abruptly
discontinued in a physically dependent patient, a withdrawal syndrome
may occur.  Some or all of the following can characterize this syndrome:
restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills,
myalgia, and mydriasis.  Other signs and symptoms also may develop,
including irritability, anxiety, backache, joint pain, weakness, abdominal
cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased
blood pressure, respiratory rate, or heart rate.</paragraph>
                        <paragraph ID="p2355324341406740530">Infants born to mothers physically dependent
on opioids will also be physically dependent and may exhibit respiratory
difficulties and withdrawal signs <content styleCode="italics">[see Use in Specific Populations
(<linkHtml href="#Section_8.1">8.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="09f45b43-8b58-7dd0-d91e-77e98559fe50"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph ID="p2358524341406740629">
                     <content styleCode="underline">Clinical Presentation</content>
                  </paragraph>
                  <paragraph ID="p2358324341406740628">Acute overdose with
TARGINIQ ER can be manifested by respiratory depression, somnolence
progressing to stupor or coma, skeletal muscle flaccidity, cold and
clammy skin, constricted pupils, and, in some cases, pulmonary edema,
bradycardia, hypotension, partial or complete airway obstruction,
atypical snoring, and death.  Marked mydriasis rather than miosis
may be seen with hypoxia in overdose situations.</paragraph>
                  <paragraph ID="p2358124341406740627">
                     <content styleCode="underline">Treatment of Overdose</content>
                  </paragraph>
                  <paragraph ID="p2357924341406740626">In case of overdose,
priorities are the reestablishment of a patent and protected airway
and institution of assisted or controlled ventilation, if needed.
 Employ other supportive measures (including oxygen, vasopressors)
in the management of circulatory shock and pulmonary edema as indicated.
 Cardiac arrest or arrhythmias will require advanced life support
techniques.</paragraph>
                  <paragraph ID="p2357724341406740626">The opioid
antagonists, naloxone or nalmefene, are specific antidotes to respiratory
depression resulting from opioid overdose.  For clinically significant
respiratory or circulatory depression secondary to oxycodone overdose,
administer an opioid antagonist.  Although TARGINIQ ER contains naloxone,
in overdose situations, administration of naloxone should be repeated
as clinically necessary.  Higher than normal doses and repeated administration
may be necessary.  Opioid antagonists should not be administered in
the absence of clinically significant respiratory or circulatory depression
secondary to oxycodone overdose.</paragraph>
                  <paragraph ID="p2357524341406740624">Because the duration of reversal is expected
to be less than the duration of action of oxycodone in TARGINIQ ER,
carefully monitor the patient until spontaneous respiration is reliably
reestablished.  TARGINIQ ER will continue to release oxycodone and
add to the oxycodone load for 24 to 48 hours or longer following ingestion,
necessitating prolonged monitoring.  If the response to an opioid
antagonist is suboptimal or only brief in nature, administer additional
antagonist as directed by the product’s prescribing information.</paragraph>
                  <paragraph ID="p2357324341406740621">In an individual physically
dependent on opioids, administration of the recommended usual dosage
of the antagonist will precipitate an acute withdrawal syndrome. 
The severity of the withdrawal symptoms experienced will depend on
the degree of physical dependence and the dose of the antagonist administered.
 If a decision is made to treat serious respiratory depression in
the physically dependent patient, administration of the antagonist
should be initiated with care and by titration with smaller than usual
doses of the antagonist.</paragraph>
               </text>
               <effectiveTime value="20161222"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="1e1e001d-d2a8-f9cc-3f32-cbce9349437e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph ID="p2356924341406740620">TARGINIQ ER (oxycodone hydrochloride and naloxone hydrochloride extended-release
tablets) is a combination product containing an opioid agonist, oxycodone,
and an opioid antagonist, naloxone.  TARGINIQ ER is supplied as 10
mg/5 mg, 20 mg/10 mg, and 40 mg/20 mg tablets for oral administration.
 The tablet strengths, a 2:1 ratio in each, describe the amount of
oxycodone and naloxone per tablet as the hydrochloride salts, respectively.
 The structural formula for oxycodone hydrochloride is as follows:</paragraph>
                  <renderMultiMedia referencedObject="g15879351441480735533"/>
                  <paragraph ID="p2356724341406740619">The chemical name is
4, 5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride.</paragraph>
                  <paragraph ID="p2356334341406740617">Oxycodone is a white, odorless
crystalline powder derived from the opium alkaloid, thebaine. Oxycodone
hydrochloride dissolves in water (1 g in 6 to 7 mL).  It is slightly
soluble in alcohol (octanol water partition coefficient 0.7).</paragraph>
                  <paragraph ID="p2382934341406740741">The structural formula for naloxone
hydrochloride is as follows:</paragraph>
                  <renderMultiMedia referencedObject="g15890351441480735639"/>
                  <paragraph ID="p2382734341406740738">The chemical name is
(-)-17-Allyl-4,5α -epoxy-3,14-dihydroxy-morphinan-6-one hydrochloride.</paragraph>
                  <paragraph ID="p2382534341406740737">Naloxone hydrochloride occurs
as a white to slightly off-white powder, and is soluble in water,
in dilute acids, and in strong alkali; slightly soluble in alcohol;
practically insoluble in ether and in chloroform.</paragraph>
                  <paragraph ID="p2382334341406740736">The 10 mg/5 mg, 20 mg/10 mg and 40 mg/20
mg extended-release tablets contain the following inactive ingredients:
 lactose monohydrate, stearyl alcohol, ethyl cellulose, povidone,
talc, magnesium stearate, polyvinyl alcohol partially hydrolyzed,
titanium dioxide, and Macrogol.  The 20 mg/10 mg extended-release
tablets also contain:  Iron oxide red.  The 40 mg/20 mg extended-release
tablets also contain:  Iron oxide yellow.</paragraph>
                  <paragraph ID="p2382144341406740735">The film-coated extended-release tablets
are color coded to distinguish different strengths as follows:<br/>The 10 mg/5 mg extended-release tablets are white.<br/>The
20 mg/10 mg extended-release tablets are pink.<br/>The 40 mg/20
mg extended-release tablets are yellow.</paragraph>
               </text>
               <effectiveTime value="20161222"/>
               <component>
                  <observationMedia ID="g15879351441480735533">
                     <text>oxycodone-hydrochloride-structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="oxycodone-hydrochloride-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="g15890351441480735639">
                     <text>naloxone-hydrochloride-structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="naloxone-hydrochloride-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="fab1f320-572e-3f53-e5d7-7776b193b3e1"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20161222"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="a677e9aa-abb8-b3e6-9a03-a0fe54a74867"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph ID="p2381934341406740728">
                           <content styleCode="underline">Oxycodone</content>
                           <br/>Oxycodone hydrochloride is a full opioid agonist and
is relatively selective for the mu receptor, although it can bind
to other opioid receptors at higher doses. The principal therapeutic
action of oxycodone is analgesia. Like all full opioid agonists, there
is no ceiling effect to analgesia for oxycodone. Clinically, dosage
is titrated to provide adequate analgesia and may be limited by adverse
reactions, including respiratory and CNS depression.</paragraph>
                        <paragraph ID="p294711451441480735709">The precise mechanism of the analgesic
action is unknown.  However, specific CNS opioid receptors for endogenous
compounds with opioid-like activity have been identified throughout
the brain and spinal cord and are thought to play a role in the analgesic
effects of this drug.</paragraph>
                        <paragraph ID="p2381734341406740727">
                           <content styleCode="underline">Naloxone</content>
                           <br/>Naloxone is an antagonist
acting on mu, kappa, and delta opioid receptors in the brain, spinal
cord, and peripheral organs (e.g, intestine, heart, kidney, and lungs).
 Naloxone antagonizes opioid effects by competing for the mu, kappa,
and delta opioid receptor sites with the greatest affinity for the
mu receptor.  Naloxone produces opioid withdrawal signs and symptoms
in individuals physically dependent on opioid agonists when administered
parenterally.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="0c04fe18-8ae9-5fb9-efff-f1f4eb9ebef6"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph ID="p2381164341406740725">
                           <content styleCode="underline">Effects on the Central
Nervous System</content>
                        </paragraph>
                        <paragraph ID="p2410234341406740901">Oxycodone produces respiratory depression
by direct action on brain stem respiratory centers.  The respiratory
depression involves a reduction in the responsiveness of the brain
stem respiratory centers to both increases in CO<sub>2</sub> tension and electrical stimulation.</paragraph>
                        <paragraph ID="p2410434341406740898">Oxycodone causes miosis, even in total darkness.
 Pinpoint pupils are a sign of opioid overdose but are not pathognomonic
(e.g., pontine lesions of hemorrhagic or ischemic origin may produce
similar findings).  Marked mydriasis rather than miosis may be seen
with hypoxia in overdose situations <content styleCode="italics">[see Overdosage (<linkHtml href="#Section_10">10</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p2410634341406740897">Naloxone prevents or reverses the effects
of opioids, including respiratory depression and sedation, when administered
intravenously <content styleCode="italics">[see Overdosage (<linkHtml href="#Section_10">10</linkHtml>)]</content>.  When naloxone is administered orally, at the same doses
as in TARGINIQ ER, these effects would not be expected due to low
circulating plasma concentrations.</paragraph>
                        <paragraph ID="p2406794341406740895">
                           <content styleCode="underline">Effects on the Gastrointestinal
Tract and Other Smooth Muscle</content>
                        </paragraph>
                        <paragraph ID="p2409134341406740893">Oxycodone causes a reduction in motility
associated with an increase in smooth muscle tone in the antrum of
the stomach and duodenum.  Digestion of food in the small intestine
is delayed and propulsive contractions are decreased.  Propulsive
peristaltic waves in the colon are decreased, while tone may be increased
to the point of spasm, resulting in constipation.  Other opioid-induced
effects may include a reduction in biliary and pancreatic secretions,
spasm of sphincter of Oddi, and transient elevations in serum amylase.</paragraph>
                        <paragraph ID="p695224341406740891">
                           <content styleCode="underline">Effects on the Cardiovascular
System</content>
                        </paragraph>
                        <paragraph ID="p2409024341406740881">Oxycodone produces peripheral vasodilation, which may result in orthostatic
hypotension or syncope.   Manifestations of histamine release and/or
peripheral vasodilation may include pruritus, flushing, red eyes,
sweating, and/or orthostatic hypotension.</paragraph>
                        <paragraph ID="p2408634341406740880">
                           <content styleCode="underline">Effects on the Endocrine System</content>
                        </paragraph>
                        <paragraph ID="p2407944341406740876">Opioids inhibit
the secretion of adrenocorticotropic hormone (ACTH), cortisol, and
luteinizing hormone (LH) in humans <content styleCode="italics">[see Adverse Reactions
(6.2)]</content>.  They also stimulate prolactin, growth hormone (GH)
secretion, and pancreatic secretion of insulin and glucagon.</paragraph>
                        <paragraph ID="p16417451441480735879">Chronic use of opioids may
influence the hypothalamic-pituitary-gonadal axis, leading to androgen
deficiency that may manifest as low libido, impotence, erectile dysfunction,
amenorrhea, or infertility. The causal role of opioids in the clinical
 syndrome of hypogonadism is unknown because the various medical,
physical, lifestyle, and psychological stressors that may influence
gonadal hormone levels have not been adequately controlled for in
studies conducted to date <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6.2">6.2</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p2457814341406741295">
                           <content styleCode="underline">Effects on the Immune System</content>
                        </paragraph>
                        <paragraph ID="p2457614341406741294">Opioids have been
shown to have a variety of effects on components of the immune system
in in vitro and animal models.  The clinical significance of these
findings is unknown.  Overall, the effects of opioids appear to be
modestly immunosuppressive.</paragraph>
                        <paragraph ID="p2436824341406741292">
                           <content styleCode="underline">Concentration –Efficacy Relationships</content>
                        </paragraph>
                        <paragraph ID="p2436634341406741290">Studies with oxycodone
in normal volunteers and patients reveal predictable relationships
between oxycodone dosage and plasma oxycodone concentrations, as well
as between concentration and certain expected opioid effects, such
as pupillary constriction, sedation, overall subjective “drug effect”,
and analgesia.</paragraph>
                        <paragraph ID="p2436424341406741286">The
minimum effective analgesic concentration will vary widely among patients,
especially among patients who have been previously treated with potent
agonist opioids.  The minimum effective analgesic concentration of
oxycodone for any individual patient may increase over time due to
an increase in pain, the development of a new pain syndrome, and/or
the development of analgesic tolerance <content styleCode="italics">[see Dosage and Administration
(<linkHtml href="#Section_2.1">2.1</linkHtml>, <linkHtml href="#Section_2.3">2.3</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p2436224341406741285">
                           <content styleCode="underline">Concentration –Adverse Reaction Relationships</content>
                        </paragraph>
                        <paragraph ID="p2436024341406741284">There is a relationship between
increasing oxycodone plasma concentration and increasing frequency
of dose-related opioid adverse reactions such as nausea, vomiting,
CNS effects, and respiratory depression.  In opioid-tolerant patients,
the situation may be altered by the development of tolerance to opioid-related
adverse reactions <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#Section_2.1">2.1</linkHtml>, <linkHtml href="#Section_2.2">2.2</linkHtml>, <linkHtml href="#Section_2.3">2.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="96007475-5688-40b0-2aae-6b40ab6ed86d"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph ID="p2435624341406741282">The analgesic activity of TARGINIQ
ER is primarily due to the parent drug oxycodone.  TARGINIQ ER is
designed to provide delivery of oxycodone over 12 hours.</paragraph>
                        <paragraph ID="p2435424341406741281">Cutting, breaking, chewing,
crushing, or dissolving TARGINIQ ER impairs the extended-release delivery
mechanism and results in the rapid release and absorption of a potentially
fatal dose of oxycodone.</paragraph>
                        <paragraph ID="p2433294341406741279">
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph ID="p2484544341406741424">
                           <content styleCode="italics">Oxycodone </content>
                           <br/>Oxycodone
from TARGINIQ ER tablets was rapidly absorbed with the median T<sub>max</sub> 3 to 4 hours following a single oral administration
over a range of doses from 10 mg/5 mg to 80 mg/40 mg.  About 60% to
87% of an oral dose of oxycodone reaches the central compartment in
comparison to a parenteral dose. This high oral bioavailability is
due to low pre-systemic and/or first-pass metabolism. Dose proportionality
for oxycodone has been established for the 10 mg/5 mg, 20 mg/10 mg,
and 40 mg/20 mg TARGINIQ ER tablet strengths for both peak plasma
concentrations (C<sub>max</sub>) and extent of absorption
(AUC) (see Table 8 and Table 9, below) following single or multiple
oral dose with q12h administration. Steady-state plasma concentrations
are reached in approximately 2 days for oxycodone and naloxone and
for their metabolites.</paragraph>
                        <paragraph ID="p2485954341406741423">
                           <content styleCode="italics">Naloxone</content>
                           <br/>Absolute bioavailability of
naloxone from TARGINIQ ER tablets was very low (≤ 2%) following oral
administration. However in an abuse potential study conducted in nondependent
drug users, naloxone bioavailability was much higher (approximately
31%) following intranasal administration of crushed TARGINIQ ER 40
mg/20 mg tablets, due to circumvention of GI and hepatic first-pass
naloxone metabolism. Mean AUC and C<sub>max</sub> values
of naloxone were 29.9 nghr/mL and 20.2 ng/mL following intranasal
administration of crushed TARGINIQ ER 40 mg/20 mg tablets, while mean
AUC and C<sub>max</sub> values were 0.833 ng hr/mL  and
0.0845 ng/mL under normal use condition <content styleCode="italics">[see Drug Abuse and
Dependence (<linkHtml href="#Section_9.2">9.2</linkHtml>)].</content>
                        </paragraph>
                        <table ID="t250942434" border="0" frame="void" rules="none" width="100%">
                           <caption>Table 9.  Pharmacokinetic Parameters for Oxycodone (Mean
[SD])</caption>
                           <colgroup>
                              <col width="18%"/>
                              <col width="18%"/>
                              <col width="16%"/>
                              <col width="16%"/>
                              <col width="16%"/>
                              <col width="16%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="6">† for single-dose, AUC = AUC<sub>0-inf</sub>; for multiple-dose, AUC = AUC<sub>tau</sub>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6">†† median (range)</td>
                              </tr>
                              <tr>
                                 <td colspan="6">Data obtained from healthy subjects receiving naltrexone.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr valign="top">
                                 <td styleCode="Botrule" align="center">Regimen</td>
                                 <td styleCode="Botrule" align="center">TARGINIQ ER Dose (mg/mg)</td>
                                 <td styleCode="Botrule" align="center">AUC (ng•hr/mL)†</td>
                                 <td styleCode="Botrule" align="center">C<sub>max</sub>
                                    <br/>(ng/mL)</td>
                                 <td styleCode="Botrule" align="center">T<sub>max</sub>
                                    <br/>(hour) ††</td>
                                 <td styleCode="Botrule" align="center">Trough Conc. (ng/mL)</td>
                              </tr>
                              <tr>
                                 <td align="center">Single Dose</td>
                                 <td>10/5</td>
                                 <td>130 [25.6]</td>
                                 <td>12.1 [2.67]</td>
                                 <td>3 [1, 6]</td>
                                 <td>NA</td>
                              </tr>
                              <tr>
                                 <td align="center"> </td>
                                 <td>20/10</td>
                                 <td>247 [62.7]</td>
                                 <td>22.2 [4.19]</td>
                                 <td>3 [1, 6]</td>
                                 <td>NA</td>
                              </tr>
                              <tr>
                                 <td align="center"> </td>
                                 <td>40/20</td>
                                 <td>506 [128]</td>
                                 <td>40.9 [9.52]</td>
                                 <td>3.5 [1, 6]</td>
                                 <td>NA</td>
                              </tr>
                              <tr>
                                 <td colspan="6" align="center"> </td>
                              </tr>
                              <tr>
                                 <td align="center">Multiple Dose</td>
                                 <td>10/5  q12h</td>
                                 <td>129 [33.4]</td>
                                 <td>15.0 [3.25]</td>
                                 <td>1.75 [1, 5]</td>
                                 <td>5.69 [1.78]</td>
                              </tr>
                              <tr>
                                 <td align="center"> </td>
                                 <td>40/20 q12h</td>
                                 <td>507 [100]</td>
                                 <td>57.0 [10.0]</td>
                                 <td>2 [0.5, 5]</td>
                                 <td>24.7 [5.68]</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="t266721434" border="0" frame="void" rules="none" width="100%">
                           <caption>Table 10.  Pharmacokinetic Parameters for Naloxone (Mean
[SD])</caption>
                           <colgroup>
                              <col width="18%"/>
                              <col width="18%"/>
                              <col width="16%"/>
                              <col width="16%"/>
                              <col width="16%"/>
                              <col width="16%"/>
                           </colgroup>
                           <tfoot>
                              <tr>
                                 <td colspan="6">† for single-dose, AUC = AUC<sub>0-inf</sub>; for multiple-dose, AUC = AUC<sub>tau</sub>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="6">†† median (range)</td>
                              </tr>
                              <tr>
                                 <td colspan="6">Data obtained from healthy subjects receiving naltrexone.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr valign="top">
                                 <td styleCode="Botrule" align="center">Regimen</td>
                                 <td styleCode="Botrule" align="center">TARGINIQ ER Dose (mg/mg)</td>
                                 <td styleCode="Botrule" align="center">AUC (ng•hr/mL)†</td>
                                 <td styleCode="Botrule" align="center">C<sub>max</sub>
                                    <br/>(ng/mL)</td>
                                 <td styleCode="Botrule" align="center">T<sub>max</sub>
                                    <br/>(hour) ††</td>
                                 <td styleCode="Botrule" align="center">Trough Conc. (ng/mL)</td>
                              </tr>
                              <tr>
                                 <td align="center">Single Dose</td>
                                 <td>10/5</td>
                                 <td>0.136 [0.141]</td>
                                 <td>0.0306 [0.0236]</td>
                                 <td>5 [1, 12]</td>
                                 <td>NA</td>
                              </tr>
                              <tr>
                                 <td align="center"> </td>
                                 <td>20/10</td>
                                 <td>0.657 [0.585]</td>
                                 <td>0.0839 [0.0812]</td>
                                 <td>1.5 [0.5, 12]</td>
                                 <td>NA</td>
                              </tr>
                              <tr>
                                 <td align="center"> </td>
                                 <td>40/20</td>
                                 <td>0.833 [0.526]</td>
                                 <td>0.0845 [0.0834]</td>
                                 <td>2 [1, 16]</td>
                                 <td>NA</td>
                              </tr>
                              <tr>
                                 <td colspan="6" align="center"> </td>
                              </tr>
                              <tr>
                                 <td align="center">Multiple Dose</td>
                                 <td>10/5  q12h</td>
                                 <td>0.416 [0.367]</td>
                                 <td>0.0725 [0.0885]</td>
                                 <td>3.75 [0.5, 8]</td>
                                 <td>0.0154 [0.00882]</td>
                              </tr>
                              <tr>
                                 <td align="center"> </td>
                                 <td>40/20 q12h</td>
                                 <td>1.55 [1.02]</td>
                                 <td>0.217 [0.173]</td>
                                 <td>5 [0.5, 12]</td>
                                 <td>0.0711 [0.0410]</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph ID="p2484944341406741422">Food Effect:</paragraph>
                        <paragraph ID="p2485344341406741421">Administration of TARGINIQ ER
with a standardized high-fat meal did not meaningfully affect the
extent of absorption of oxycodone, naloxone, or naloxone-3β-glucuronide.
 In the clinical trial program, TARGINIQ ER was administered to chronic
pain patients without regard to meals.  Therefore, TARGINIQ ER can
be administered with or without food.</paragraph>
                        <paragraph ID="p2484344341406741420">
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph ID="p2486544341406741419">
                           <content styleCode="italics">Oxycodone</content>
                           <br/>Plasma protein binding for oxycodone measured in healthy subjects
was &lt;24%. Following IV administration, the mean volume of distribution
for oxycodone (0.07 mg/kg) was 245 L. Once absorbed, oxycodone is
distributed to skeletal muscle, liver, intestinal tract, lungs, spleen,
and brain. Oxycodone is found in breast milk <content styleCode="italics">[see Use in Specific
Populations (<linkHtml href="#Section_8.3">8.3</linkHtml>)]</content>.  Oxycodone
crossed the blood-brain barrier in preclinical species.</paragraph>
                        <paragraph ID="p2484224341406741418">
                           <content styleCode="italics">Naloxone</content>
                           <br/>Plasma protein binding for naloxone measured in healthy subjects,
was &lt;60%. Following IV administration, the mean volume of distribution
for naloxone (0.035 mg/kg) was 378 L. It is not known whether naloxone
passes into breast milk.  Naloxone crossed the blood-brain barrier
in preclinical species.</paragraph>
                        <paragraph ID="p16919651441480736300">
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph ID="p2461394341406741417">
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph ID="p2484114341406741410">Oxycodone:<br/>Oxycodone metabolism
is primarily mediated by CYP3A4/5 and CYP2D6. Oxycodone is mainly
metabolized to Phase 1 metabolites including noroxycodone, oxymorphone
and noroxymorphone.  Oxycodone metabolites are present in plasma at
lower concentrations than the parent drug.  Noroxycodone and noroxymorphone
are the major metabolites in the blood circulation.  The mean molar
ratio of metabolite to parent (oxycodone), as evaluated by AUC across
proposed therapeutic doses of TARGINIQ ER, was 0.928 for noroxycodone,
0.379 for noroxymorphone, and 0.0251 for oxymorphone, respectively.</paragraph>
                        <paragraph ID="p2483914341406741409">Naloxone:<br/>Naloxone
metabolism is primarily mediated by UGT1A8 and UGT2B7.  Naloxone is
mainly metabolized to 6β-naloxol, naloxone-3β-glucuronide and 6β-naloxol-3β-glucuronide.
 The mean molar ratio of metabolite to parent (naloxone), as evaluated
by AUC across proposed therapeutic doses TARGINIQ ER was 31.5 for
6β-naloxol, 1459 for naloxone-3β-glucuronide, and 1301 for 6β-naloxol-3β-glucuronide,
respectively.  Naloxone metabolites were present in plasma at higher
concentrations than the parent drug, especially for naloxone-3β-glucuronide
and 6β-naloxol-3β-glucuronide due to the extremely low plasma naloxone
concentrations following oral administration of TARGINIQ ER.</paragraph>
                        <paragraph ID="p2483714341406741408">
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph ID="p2483514341406741407">Oxycodone:<br/>Oxycodone
is rapidly eliminated from the body with a mean t<sub>1/2</sub> of approximately 3.9-5.3 hours after a single oral dose administration
of TARGINIQ ER in healthy subjects.  Oxycodone and its metabolites
are excreted in both urine and feces.  Following an IV dose (0.07
mg/kg), the mean total plasma clearance was 47.8 L/hour in healthy
subjects.  Following TARGINIQ ER 10/5 mg administration, the mean
renal clearance was approximately 3.66-4.37 L/hour.  Following an
oral dose of oxycodone immediate-release (15 mg), the mean total urine
recovery (48 hour cumulative recovery) of oxycodone and its metabolites
from 16 healthy subjects was 72%.  These findings suggest that metabolism
is the major route of elimination.</paragraph>
                        <paragraph ID="p2483314341406741406">Naloxone:<br/>Naloxone is eliminated
from the body with mean t<sub>1/2</sub> ranging from 4.1
to 17.2 hours after a single oral dose administration of TARGINIQ
ER in healthy subjects.  The mean total plasma clearance was 217 L/hour
following an IV dose (0.035 mg/kg), and the mean renal clearance was
7.85-31.9 L/hour following an oral dose of TARGINIQ ER 10 mg/5 mg.
These findings suggest that the metabolism is the major route of elimination.</paragraph>
                        <paragraph ID="p2461744341406741405">
                           <content styleCode="underline">Special Populations</content>
                        </paragraph>
                        <paragraph ID="p2715064341406742314">
                           <content styleCode="italics">Age: Geriatric
Population</content>
                        </paragraph>
                        <paragraph ID="p2715254341406742313">A prospective study conducted in 2 age groups (younger: 19-44 years
old vs. elderly: 65-77 years old) to assess age effects on the PK
of TARGINIQ ER (10 mg/5 mg) demonstrated slightly higher steady state
oxycodone AUC (18% increase), and higher steady state naloxone AUC
(82% increase) for elderly subjects compared with younger subjects. <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.6">8.6</linkHtml>)]</content>
                        </paragraph>
                        <paragraph ID="p2715854341406742312">
                           <content styleCode="italics">Sex</content>
                        </paragraph>
                        <paragraph ID="p2716654341406742309">Pharmacokinetic
properties of TARGINIQ ER were not affected by sex.</paragraph>
                        <paragraph ID="p2715474341406742308">
                           <content styleCode="italics">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph ID="p516284341406742306">Oxycodone:<br/>Oxycodone
pharmacokinetics from TARGINIQ ER was significantly altered by hepatic
impairment, especially in subjects with moderate or severe hepatic
impairment as compared with healthy subjects.  Mean oxycodone AUC
was 99.1, 143, 319 and 314 nghr/mL for healthy subjects, and subjects
with mild, moderate, and severe hepatic impairment, respectively.
The mean increase in oxycodone AUC was approximately 43%, 219%, and
210% for subjects with mild, moderate, and severe hepatic impairment,
respectively, as compared with that for healthy subjects. Mean oxycodone
C<sub>max</sub> was 9.00, 10.8, 18.1 and 17.2 ng/mL for
healthy subjects, and subjects with mild, moderate, and severe hepatic
impairment, respectively. The mean increase in oxycodone C<sub>max</sub> was approximately 20%, 101%, and 91% for subjects
with mild, moderate, and severe hepatic impairment, respectively,
as compared with that for healthy subjects.</paragraph>
                        <paragraph ID="p2714424341406742301">Naloxone:<br/>Following oral TARGINIQ
ER administration, mean naloxone AUC<sub>0-t</sub> was
0.115, 1.02, 0.459 and 1.12 ng•hr/mL for healthy subjects, and subjects
with mild, moderate, and severe renal impairment, respectively.  Mean
naloxone C<sub>max</sub> was 0.0345, 0.0435, 0.0347 and
0.0678 ng/mL for healthy subjects, and subjects with mild, moderate,
and severe renal impairment, respectively. The mean increase in naloxone
C<sub>max</sub> was approximately 976%, 758%, and 1575%
for subjects with mild, moderate, and severe renal impairment, respectively,
as compared with that for healthy subjects <content styleCode="italics">[see Use in Specific
Populations (<linkHtml href="#Section_8.7">8.7</linkHtml>)]</content>. </paragraph>
                        <paragraph ID="p2769624341406742554">
                           <content styleCode="italics">Renal Impairment</content>
                        </paragraph>
                        <paragraph ID="p2790814341406742565">Oxycodone:<br/>Following oral TARGINIQ ER administration, mean oxycodone AUC was
111, 171, 186 and 253 nghr/mL for healthy subjects, and subjects with
mild, moderate, and severe renal impairment, respectively.  The mean
increase in oxycodone AUC was approximately 53%, 66% and 124% for
subjects with mild, moderate and severe renal impairment, respectively,
as compared with that for healthy subjects. Mean oxycodone C<sub>max</sub> was 10.6, 11.7, 14.4 and 17.8 ng/mL for healthy subjects,
and subjects with mild, moderate, and severe renal impairment, respectively.
The mean increase in oxycodone C<sub>max</sub> was approximately
10%, 35%, and 67% for subjects with mild, moderate, and severe renal
impairment, respectively, as compared with that for healthy subjects. <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.8">8.8</linkHtml>)]</content>
                        </paragraph>
                        <paragraph ID="p2791014341406742568">Naloxone:<br/>Following oral TARGINIQ ER administration, mean naloxone AUC<sub>0-t</sub> was 0.115, 1.02, 0.459 and 1.12 nghr/mL for healthy
subjects, and subjects with mild, moderate, and severe renal impairment,
respectively.  Mean naloxone C<sub>max</sub> was 0.0345,
0.0435, 0.0347 and 0.0678 ng/mL for healthy subjects, and subjects
with mild, moderate, and severe renal impairment, respectively. The
mean increase in naloxone C<sub>max</sub> was approximately
976%, 758%, and 1575% for subjects with mild, moderate, and severe
renal impairment, respectively, as compared with that for healthy
subjects <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.8">8.8</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p358761051441480736663">
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph ID="p2791214341406742569">
                           <content styleCode="italics">Oxycodone</content>
                           <br/>At therapeutic concentrations, TARGINIQ ER is not expected
to affect concomitantly administered medicines metabolized by CYP1A2,
CYP2A6, CYP2C9/19, CYP2D6, CYP2E1 and CYP3A4.  There were no pharmacokinetic
drug interactions between oxycodone and naloxone.</paragraph>
                        <paragraph ID="p2790614341406742563">CYP3A4 Inhibitors:<br/>CYP3A4 is
the major enzyme involved in noroxycodone formation. Co-administration
of an oxycodone controlled release tablet (10 mg single dose) and
the CYP3A4 inhibitor ketoconazole (200 mg BID) increased oxycodone
AUC and C<sub>max</sub> by 170% and 100%, respectively <content styleCode="italics">[see Drug Interactions (<linkHtml href="#Section_7">7</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p19982351441480736725">CYP3A4 Inducers:<br/>A published study showed that the co-administration of rifampin,
a drug metabolizing enzyme inducer, decreased oxycodone AUC and C<sub>max</sub> values by 86% and 63%, respectively <content styleCode="italics">[see
Drug Interactions (<linkHtml href="#Section_7">7</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p10769551441480736750">CYP2D6 Inhibitors:<br/>Oxycodone is metabolized in part to oxymorphone via CYP2D6.  While
this pathway may be blocked by a variety of drugs such as certain
cardiovascular drugs (e.g., quinidine) and antidepressants (e.g.,
fluoxetine), such blockade has not been shown to be of clinical significance
with TARGINIQ ER <content styleCode="italics">[see Drug Interactions (<linkHtml href="#Section_7">7</linkHtml>)]</content>.</paragraph>
                        <paragraph ID="p10782551441480736779">
                           <content styleCode="italics">Naloxone</content>
                           <br/>UGT1A8 and 2B7 are responsible
for the metabolism of naloxone. Metabolic drug interactions with naloxone
are unknown.</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="43284501-b46e-2e57-3da3-ed145c8349a9"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20161222"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="e57f327d-e800-72d4-5313-70d5fe9d5474"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph ID="p2790414341406742561">
                           <content styleCode="underline">Carcinogenesis</content>
                           <br/>Carcinogenicity studies have not been conducted with
oxycodone alone or the oxycodone and naloxone combination.</paragraph>
                        <paragraph ID="p2769424341406742552">Naloxone was tested in two carcinogenicity
studies in rats and transgenic mice. Naloxone was not carcinogenic
in a 2-year rat bioassay at doses as high as 100 mg/kg/day (24-times
the maximum recommended daily dose of 40 mg naloxone/day on a mg/m<sup>2</sup> basis).</paragraph>
                        <paragraph ID="p2769224341406742551">Naloxone did not produce evidence of carcinogenic potential in the
Tg.rasH2 mouse model.</paragraph>
                        <paragraph ID="p2769024341406742549">
                           <content styleCode="underline">Mutagenesis</content>
                           <br/>Oxycodone was genotoxic
in the mouse lymphoma assay.  Clastogenicity was observed with oxycodone
in the presence of metabolic activation in one chromosomal aberration
assay in human lymphocytes at concentrations greater than or equal
to 1250 mcg/mL at 24 but not 48 hours of exposure.  In a second chromosomal
aberration assay with human lymphocytes, no structural clastogenicity
was observed either with or without metabolic activation; however,
in the absence of metabolic activation, oxycodone increased numerical
chromosomal aberrations (polyploidy).  Oxycodone was not genotoxic
in the following assays: Ames <content styleCode="italics">S. typhimurium</content> and <content styleCode="italics">E. coli</content> test with and without metabolic activation at concentrations
up to 5000 µg/plate, chromosomal aberration test in human lymphocytes
(in the absence of metabolic activation) at concentrations up to 1500
µg/mL, and with activation after 48 hours of exposure at concentrations
up to 5000 µg/mL, and in the <content styleCode="italics">in vivo</content> bone marrow
micronucleus assay in mice (at plasma levels up to 48 µg/mL).</paragraph>
                        <paragraph ID="p2768824341406742547">Naloxone was genotoxic in the
mouse lymphoma assay.  Naloxone produced a non-dose-related increase
in chromosomal aberrations in the presence of metabolic activation
that was statistically significant at concentrations of 375 and 1500
mcg/mL but not at 750 or 3000 mcg/mL.  In contrast, naloxone was not
mutagenic in the <content styleCode="italics">S. typhimurium</content>/<content styleCode="italics">E. coli</content> bacterial mutagenicity test with or without metabolic activation
nor was it genotoxic in <content styleCode="italics">in vivo</content> mouse bone marrow
micronucleus test at a dose of 500 mg/kg.</paragraph>
                        <paragraph ID="p2768624341406742546">
                           <content styleCode="underline">Impairment of Fertility</content>
                           <br/>Fertility studies to evaluate the combination of oxycodone
and naloxone have not been conducted.  In a study of reproductive
performance, rats were administered a once daily gavage dose of the
vehicle or oxycodone hydrochloride doses up to 8 mg/kg (equivalent
to the maximum recommended daily dose of 80 mg/day on a mg/m<sup>2</sup> basis).  Male rats were dosed for 28 days before
cohabitation with females, during the cohabitation and until necropsy
(2-3 weeks post-cohabitation).  Females were dosed for 14 days before
cohabitation with males, during cohabitation and up to Gestation Day
6.  Oxycodone hydrochloride did not affect reproductive function in
male or female rats.</paragraph>
                        <paragraph ID="p2768424341406742544">Oral administration of naloxone to male and female rats at dosages
as high as 800 mg/kg/day had no effect on fertility or general reproductive
performance (approximately 192-times the maximum recommended daily
dose of 40 mg naloxone/day, on a mg/m<sup>2</sup> basis).</paragraph>
                     </text>
                     <effectiveTime value="20161222"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_14">
               <id root="57c541ce-f9fc-6531-ce7d-5cd7b960c76c"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph ID="p2768224341406742542">The efficacy of TARGINIQ ER
was evaluated in one 12-week, randomized, double-blind, placebo-controlled
clinical trial in opioid-experienced patients with uncontrolled moderate
to severe chronic low back pain.</paragraph>
                  <paragraph ID="p2768024341406742540">
                     <content styleCode="underline">12-Week Study in Opioid-Experienced
Patients with Uncontrolled Chronic Low Back Pain</content>
                     <br/>A total of 1095 patients (mean age = 52 years [range 20-88]; 45%
male and 55% female) with uncontrolled moderate to severe chronic
low back pain entered an open-label, dose-titration period for up
to four weeks.  Patients initiated TARGINIQ ER therapy at an oxycodone
dose approximately equivalent to their current therapy <content styleCode="italics">[see
Dosage and Administration (<linkHtml href="#Section_2.1">2.1</linkHtml>)]</content>.  The dose of TARGINIQ ER could be up-titrated to a maximum of 40/20
mg twice daily by the investigator every 1-2 days as needed based
on efficacy, safety, and tolerability considerations or down-titrated
at any time for safety and/or tolerability reasons.  During open-label
titration, subjects were allowed supplemental pain medication (immediate-release
oxycodone HCl 5 mg capsules) for low back pain every 4 hours as needed
up to 8 capsules per day.</paragraph>
                  <paragraph ID="p2767824341406742538">Fifty-five percent (55%) of patients who
entered the open-label titration period achieved adequate analgesia
and tolerability on TARGINIQ ER and were then randomized to their
final titrated dose of TARGINIQ ER or matching placebo for 12 weeks
of double-blind treatment.  Nine percent (9%) of patients discontinued
from the open-label titration period due to an adverse event; 10%
discontinued due to lack of a therapeutic effect, and 11% discontinued
for other reasons.  Sixteen (16%) percent did not qualify for randomization.
 During double-blind treatment, subjects were allowed one capsule
of supplemental pain medication (immediate-release oxycodone HCl 5
mg capsules) for low back pain as needed, up to 2 capsules per day.</paragraph>
                  <paragraph ID="p2871224341406742904">Of the 298 patients randomized
to TARGINIQ ER, 73% of the patients completed the 12-week double-blind
treatment on study drug.  Of the 302 patients randomized to placebo,
60% of the patients completed the study.  Fewer patients randomized
to TARGINIQ ER discontinued due to lack of efficacy compared to placebo,
10% versus 24%.  Discontinuation due to adverse events was the same
for both TARGINIQ ER (8%) and placebo (8%).</paragraph>
                  <paragraph ID="p2871024341406742903">Of the patients who were randomized, pain
scores were similar at screening and end of the open-label titration
for TARGINIQ ER and placebo subjects.  The mean average pain over
the last 24 hours (SE) scores were 7.0 (0.06) and 7.1 (0.06) at screening
and 3.1 (0.06) and 3.1 (0.06) at pre-randomization (beginning of double-blind
phase) for the TARGINIQ ER and placebo groups, respectively.</paragraph>
                  <paragraph ID="p2870824341406742902">The mean score of average pain
over the last 24 hours at the end of the study (Week 12/Early Termination)
was statistically significantly lower in patients treated with TARGINIQ
ER (SE), 3.9 (0.1), compared to patients treated with placebo (SE),
4.3 (0.1).</paragraph>
                  <paragraph ID="p2892824341406742916">A plot
of distribution of responders based on pain intensity at week 12 is
shown in Figure 4 below.  The figure is cumulative, such that patients
whose change from baseline, for example 50%, are also included at
every level of improvement below 50%.  Patients who did not complete
the study were assigned 0% improvement.  A higher proportion of patients
treated with TARGINIQ ER (55%) had at least a 30% reduction in pain
score from screening to week 12 compared to placebo patients (41%).
 Also, a higher proportion of patients treated with TARGINIQ ER (37%)
had at least a 50% reduction in pain score from screening to week
12 compared to placebo patients (25%).</paragraph>
                  <paragraph ID="p6676154341406742915">
                     <content styleCode="bold">Figure 4.  Plot of Distribution of
Responders Based on Pain Intensity at Week 12</content>
                  </paragraph>
                  <renderMultiMedia referencedObject="g29703551441480737122"/>
               </text>
               <effectiveTime value="20161222"/>
               <component>
                  <observationMedia ID="g29703551441480737122">
                     <text>figure-4</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="figure-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="81160d3c-09cd-d44d-6721-fcea85dcc45e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE
AND HANDLING</title>
               <text>
                  <paragraph ID="p721634341406742913">TARGINIQ ER (oxycodone hydrochloride and naloxone hydrochloride extended-release
tablets) 10 mg/5 mg are capsule shaped, white film-coated tablets
debossed with “ONX” on one side and “10” on the other and are supplied
as child-resistant closure, opaque HDPE bottles of 100<br/>
                     <content styleCode="bold">(NDC 59011-520-01).</content>
                  </paragraph>
                  <paragraph ID="p6422154341406742911">TARGINIQ ER (oxycodone hydrochloride and
naloxone hydrochloride extended-release tablets) 20 mg/10 mg are capsule
shaped, pink film-coated tablets debossed with “ONX” on one side and
“20” on the other and are supplied as child-resistant closure, opaque
HDPE bottles of 100<br/>
                     <content styleCode="bold">(NDC 59011-521-01)</content>.</paragraph>
                  <paragraph ID="p2870624341406742901">TARGINIQ ER (oxycodone hydrochloride
and naloxone hydrochloride extended-release tablets) 40 mg/20 mg are
capsule shaped, yellow film-coated tablets debossed with “ONX” on
one side and “40” on the other and are supplied as child-resistant
closure, opaque HDPE bottles of 100<br/>
                     <content styleCode="bold">(NDC 59011-522-01)</content>.</paragraph>
                  <paragraph ID="p2870424341406742900">Store at 25°C (77°F);
excursions permitted between 15°-30°C (59°-86°F) [see USP Controlled
Room Temperature].</paragraph>
                  <paragraph ID="p2870224341406742899">Dispense in tight, light-resistant container, with a child-resistant
closing.</paragraph>
                  <paragraph ID="p2869834341406742897">
                     <content styleCode="bold">CAUTION</content>
                  </paragraph>
                  <paragraph ID="p2895364341406743029">
                     <content styleCode="bold">DEA FORM REQUIRED</content>
                  </paragraph>
               </text>
               <effectiveTime value="20161222"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="00e742f1-63a9-b66a-651c-3462d995103d"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING
INFORMATION</title>
               <text>
                  <paragraph ID="p2919014341406745753">Advise the patient to read the FDA-approved patient labeling (Medication
Guide).</paragraph>
                  <paragraph ID="p2918814341406745752">
                     <content styleCode="underline">Addiction, Abuse, and Misuse</content>
                  </paragraph>
                  <paragraph ID="p2918614341406745751">Inform patients that the use of TARGINIQ
ER, even when taken as recommended, can result in addiction, abuse,
and misuse, which can lead to overdose and death <content styleCode="italics">[see Warnings
and Precautions (<linkHtml href="#Section_5.1">5.1</linkHtml>)].  </content>Instruct patients not to share TARGINIQ ER with others and to take
steps to protect TARGINIQ ER from theft or misuse.</paragraph>
                  <paragraph ID="p2918414341406745751">
                     <content styleCode="underline">Life-Threatening Respiratory
Depression</content>
                  </paragraph>
                  <paragraph ID="p2897624341406745750">Inform patients of the risk of life-threatening respiratory depression
including information that the risk is greatest when starting TARGINIQ
ER or when the dose is increased and that it can occur even at recommended
dosages <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>.  Advise patients how to recognize respiratory
depression and to seek medical attention if breathing difficulties
develop.</paragraph>
                  <paragraph ID="p2897424341406745749">
                     <content styleCode="underline">Accidental Ingestion</content>
                  </paragraph>
                  <paragraph ID="p2897224341406745748">Inform patients that accidental ingestion,
especially by children, may result in respiratory depression or death <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.2">5.2</linkHtml>)]</content>.  Instruct patients to take steps to store TARGINIQ ER
securely and to dispose of unused TARGINIQ ER by flushing the tablets
down the toilet.</paragraph>
                  <paragraph ID="p2897024341406745747">
                     <content styleCode="underline">Interaction with Benzodiazepines and Other CNS Depressants</content>
                  </paragraph>
                  <paragraph ID="p2896824341406745746">Inform patients
and caregivers that potentially fatal additive effects may occur if
TARGINIQ ER is used with benzodiazepines or other CNS depressants,
including alcohol, and not to use these concomitantly unless supervised
by a healthcare provider <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.5">5.5</linkHtml>), Drug Interactions (<linkHtml href="#Section_7">7</linkHtml>)].</content>
                  </paragraph>
                  <paragraph ID="p2896624341406745745">
                     <content styleCode="underline">Serotonin Syndrome</content>
                  </paragraph>
                  <paragraph ID="p2895654341406745744">Inform patients
that opioids could cause a rare but potentially life-threatening condition
resulting from concomitant administration of serotonergic drugs. Warn
patients of the symptoms of serotonin syndrome and to seek medical
attention right away if symptoms develop. Instruct patients to inform
their physicians if they are taking, or plan to take serotonergic
medications<content styleCode="italics"> [see Drug Interactions (<linkHtml href="#Section_7">7</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p2970214341406745887">
                     <content styleCode="underline">MAOI Interaction</content>
                  </paragraph>
                  <paragraph ID="p2970014341406745886">
                     <content styleCode="underline">Inform patients to avoid taking
TARGINIQ ER while using any drugs that inhibit monoamine oxidase.
Patients should not start MAOIs while taking TARGINIQ ER.</content>
                  </paragraph>
                  <paragraph ID="p205021151441480737367">
                     <content styleCode="underline">Adrenal
Insufficiency</content>
                  </paragraph>
                  <paragraph ID="p205031551441480737378">Inform patients that opioids could cause
adrenal insufficiency, a potentially life-threatening condition. Adrenal
insufficiency may present with non-specific symptoms and signs such
as nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low
blood pressure. Advise patients to seek medical attention if they
experience a constellation of these symptoms <content styleCode="italics">[see Warnings
and Precautions (<linkHtml href="#Section_5.7">5.7</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p10793751441480737398">
                     <content styleCode="underline">Important Administration
Instructions</content>
                  </paragraph>
                  <paragraph ID="p10794851441480737406">Instruct patients how to properly take
TARGINIQ ER, including the following:</paragraph>
                  <list listType="unordered" ID="l2971214341406745904" styleCode="Disc">
                     <item>TARGINIQ ER is designed to work properly only if swallowed
intact. Taking cut, broken, chewed, crushed, or dissolved TARGINIQ
ER tablets can result in a fatal overdose or other serious side effects
(e.g., withdrawal symptoms) <content styleCode="italics">[see Dosage and Administration
(<linkHtml href="#Section_2.1">2.1</linkHtml>)]</content>.</item>
                     <item>Do not discontinue TARGINIQ ER without first discussing
the need for a tapering regimen with the prescriber <content styleCode="italics">[see Dosage
and Administration (<linkHtml href="#Section_2.7">2.7</linkHtml>)]</content>.</item>
                  </list>
                  <paragraph ID="p2969814341406745883">
                     <content styleCode="underline">Hypotension</content>
                  </paragraph>
                  <paragraph ID="p2969614341406745882">Inform patients
that TARGINIQ ER may cause orthostatic hypotension and syncope.  Instruct
patients how to recognize symptoms of low blood pressure and how to
reduce the risk of serious consequences should hypotension occur (e.g.,
sit or lie down, carefully rise from a sitting or lying position) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#Section_5.8">5.8</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p2948824341406745880">
                     <content styleCode="underline">Anaphylaxis</content>
                  </paragraph>
                  <paragraph ID="p2947744341406745878">Inform patients that anaphylaxis has been reported with ingredients
contained in TARGINIQ ER.  Advise patients how to recognize such a
reaction and when to seek medical attention <content styleCode="italics">[see Contraindications
(4), Adverse Reactions (6)]</content>.</paragraph>
                  <paragraph ID="p2948544341406745877">
                     <content styleCode="underline">Pregnancy</content>
                  </paragraph>
                  <paragraph ID="p2998124341406745951">
                     <content styleCode="italics">Neonatal Opioid Withdrawal
Syndrome</content>
                     <br/>Inform female patients of reproductive
potential that prolonged use of TARGINIQ ER during pregnancy can result
in neonatal opioid withdrawal syndrome, which may be life-threatening
if not recognized and treated <content styleCode="italics">[see Warnings and Precautions
(<linkHtml href="#Section_5.3">5.3</linkHtml>), Use in Specific Populations
(<linkHtml href="#Section_8.1">8.1</linkHtml>)].</content>
                  </paragraph>
                  <paragraph ID="p2998724341406745966">
                     <content styleCode="italics">Embryo-Fetal Toxicity</content>
                     <br/>Inform female patients of reproductive potential that TARGINIQ ER
can cause fetal harm and to inform the healthcare provider of a known
or suspected pregnancy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.1">8.1</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p2998524341406745965">
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph ID="p2998334341406745960">Advise patients that breastfeeding
is not recommended during treatment with TARGINIQ ER <content styleCode="italics">[see
Use in Specific Populations (<linkHtml href="#Section_8.2">8.2</linkHtml>)]</content>
                  </paragraph>
                  <paragraph ID="p2997924341406745950">
                     <content styleCode="underline">Infertility</content>
                     <br/>Inform patients that chronic use of opioids may cause
reduced fertility. It is not known whether these effects on fertility
are reversible <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#Section_8.3">8.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph ID="p2997724341406745948">
                     <content styleCode="underline">Opioid Withdrawal Symptoms</content>
                  </paragraph>
                  <paragraph ID="p2997524341406745947">Advise patients
that TARGINIQ ER may be associated with symptoms possibly related
to opioid withdrawal, including sweating, tremors, anxiety, chills,
diarrhea, abdominal pain, irritability, and yawning, and to contact
their prescriber if these symptoms occur.</paragraph>
                  <paragraph ID="p21808451441480737678">
                     <content styleCode="underline">Driving or Operating Heavy Machinery</content>
                  </paragraph>
                  <paragraph ID="p37123351441480737681">Inform patients
that TARGINIQ ER may impair the ability to perform potentially hazardous
activities such as driving a car or operating heavy machinery.  Advise
patients not to perform such tasks until they know how they will react
to the medication.</paragraph>
                  <paragraph ID="p37124451441480737690">
                     <content styleCode="underline">Constipation</content>
                  </paragraph>
                  <paragraph ID="p37127451441480737698">Advise patients of the potential for severe
constipation, including management instructions and when to seek medical
attention <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#Section_6">6</linkHtml>)]</content>.</paragraph>
                  <paragraph ID="p37142351441480737721">
                     <content styleCode="underline">Disposal of Unused TARGINIQ ER</content>
                  </paragraph>
                  <paragraph ID="p37143451441480737736">Advise patients to flush the
unused tablets down the toilet when TARGINIQ ER is no longer needed.</paragraph>
                  <paragraph ID="p2997324341406745946">Healthcare professionals can
telephone Purdue Pharma’s Medical Services Department (1-888-726-7535)
for information on this product.</paragraph>
                  <paragraph ID="p2997124341406745946">
                     <content styleCode="bold">Purdue Pharma L.P.<br/>Stamford,
CT 06901-3431</content>
                  </paragraph>
                  <paragraph ID="p2996924341406745945">©2016, Purdue Pharma L.P.</paragraph>
                  <paragraph ID="p2995564341406745943">U.S. Patent Numbers: 6,228,863; 6,627,635;
8,822,487; 8,846,090; 8,846,091; 8,969,369; 9,056,051; 9,073,933;
9,084,729;  9,161,937; 9,168,252;  9,205,082; 9,283,216; 9,283,221;
9,345,701; 9,358,230; 9,474,750; 9,480,685; 9,511,066 and 9,522,919</paragraph>
               </text>
               <effectiveTime value="20161222"/>
            </section>
         </component>
         <component>
            <section ID="s7174134341406730487">
               <id root="98dd579f-6bed-ba6f-cd07-d0aafb472cad"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table ID="t642110434" border="0" frame="void" rules="none" width="100%">
                     <colgroup>
                        <col width="50%"/>
                        <col width="50%"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Botrule Lrule Rrule" colspan="2">
                              <content styleCode="bold">Medication
Guide<br/>TARGINIQ™ ER (tar-gih-NEEK E-R)<br/>(oxycodone
hydrochloride and naloxone hydrochloride extended-release tablets),
CII</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Lrule Rrule" colspan="2">
                              <content styleCode="bold">TARGINIQ ER
is:</content>
                              <list listType="unordered" ID="l3097924341406746612" styleCode="Disc">
                                 <item>A strong prescription pain medicine that contains an opioid
(narcotic) that is used to manage pain severe enough to require daily,
around-the-clock, long-term treatment with an opioid, when other pain
treatments such as non-opioid pain medicines or immediate-release
opioid medicines do not treat your pain well enough or you cannot
tolerate them.</item>
                                 <item>A long-acting (extended-release) opioid pain medicine that
can put you at risk for overdose and death. Even if you take your
dose correctly as prescribed you are at risk for opioid addiction,
abuse, and misuse that can lead to death.</item>
                                 <item>Not for use to treat pain that is not around-the-clock.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Lrule Rrule" colspan="2">
                              <content styleCode="bold">Important
information about TARGINIQ ER:</content>
                              <list listType="unordered" ID="l3074984341406746690" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Get emergency help right away if you take too much
TARGINIQ ER (overdose).</content> When you first start taking TARGINIQ
ER, when your dose is changed, or if you take too much (overdose),
serious or life-threatening breathing problems that can lead to death
may occur.</item>
                                 <item>Taking TARGINIQ ER with other opioid medicines, benzodiazepines,
alcohol, or other central nervous system depressants (including street
drugs) can cause severe drowsiness, decreased awareness, breathing
problems, coma, and death.</item>
                                 <item>Never give anyone else your TARGINIQ ER. They could die
from taking it. Store TARGINIQ ER away from children and in a safe
place to prevent stealing or abuse. Selling or giving away TARGINIQ
ER is against the law.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Lrule Rrule" colspan="2">
                              <content styleCode="bold">Do not take
TARGINIQ ER if you have:</content>
                              <list listType="unordered" ID="l3124434341406746780" styleCode="Disc">
                                 <item>severe asthma, trouble breathing, or other lung problems.</item>
                                 <item>a bowel blockage or have narrowing of the stomach or intestines.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule" colspan="2">
                              <content styleCode="bold">Before taking TARGINIQ
ER, tell your healthcare provider if you have a history of:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" valign="top">
                              <list listType="unordered" ID="l3047434341406746861" styleCode="Disc">
                                 <item>head injury, seizures</item>
                                 <item>liver, kidney, thyroid or heart problems</item>
                                 <item>abuse of street or prescription drugs, alcohol addiction,
or mental health problems</item>
                              </list>
                           </td>
                           <td styleCode="Rrule" valign="top">
                              <list listType="unordered" ID="l3150134341406746865" styleCode="Disc">
                                 <item>problems urinating</item>
                                 <item>pancreas or gallbladder problems</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Botrule Lrule Rrule" colspan="2">
                              <content styleCode="bold">Tell your healthcare
provider if you are:</content>
                              <list listType="unordered" ID="l3177314341406746948" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">pregnant or planning to become pregnant.</content>  Prolonged
use of TARGINIQ ER during pregnancy can cause withdrawal symptoms
in your newborn baby that could be life-threatening if not recognized
and treated.</item>
                                 <item>
                                    <content styleCode="bold">breastfeeding.</content> Not recommended during treatment
with TARGINIQ ER. It may harm your baby.</item>
                                 <item>taking prescription or over-the-counter medicines, vitamins,
or herbal supplements. Taking TARGINIQ ER with certain other medicines
can cause serious side effects that could lead to death.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Lrule Rrule" colspan="2">
                              <content styleCode="bold">When taking
TARGINIQ ER:</content>
                              <list listType="unordered" ID="l3226414341406747042" styleCode="Disc">
                                 <item>Do not change your dose.  Take TARGINIQ ER exactly as prescribed
by your healthcare provider. Use the lowest dose possible for the
shortest time needed.</item>
                                 <item>Take your prescribed dose every 12 hours at the same time
every day.  Do not take more than your prescribed dose in 12 hours.
If you miss a dose, take your next dose at your usual time.</item>
                                 <item>Swallow TARGINIQ ER whole.  Do not cut, break, chew, crush,
dissolve, snort, or inject TARGINIQ ER because this may cause you
to overdose and die.</item>
                                 <item>
                                    <content styleCode="bold">Call your healthcare provider if the dose you are
taking does not control your pain.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not stop taking TARGINIQ ER without talking to
your healthcare provider.</content>
                                 </item>
                                 <item>After you stop taking TARGINIQ ER, flush any unused tablets
down the toilet.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Lrule Rrule" colspan="2">
                              <content styleCode="bold">While taking
TARGINIQ ER DO NOT:</content>
                              <list listType="unordered" ID="l3280244341406747113" styleCode="Disc">
                                 <item>Drive or operate heavy machinery, until you know how TARGINIQ
ER affects you.  TARGINIQ ER can make you sleepy, dizzy, or lightheaded.</item>
                                 <item>Drink alcohol or use prescription or over-the-counter medicines
that contain alcohol.  Using products containing alcohol during treatment
with TARGINIQ ER may cause you to overdose and die.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Botrule Lrule Rrule" colspan="2">
                              <content styleCode="bold">The possible
side effects of TARGINIQ ER are:</content>
                              <list listType="unordered" ID="l3304214341406747136" styleCode="Disc">
                                 <item>constipation, nausea, sleepiness, vomiting, tiredness, headache,
dizziness, abdominal pain, anxiety, and sweating.  Call your healthcare
provider if you have any of these symptoms and they are severe.</item>
                              </list>
                              <content styleCode="bold">Get emergency medical help if you have:</content>
                              <list listType="unordered" ID="l3306314341406747158" styleCode="Disc">
                                 <item>trouble breathing, shortness of breath, fast heartbeat,
chest pain, swelling of your face, tongue, or throat, extreme drowsiness,
lightheadedness when changing positions, feeling faint, agitation,
high body temperature, trouble walking, stiff muscles, or mental changes
such as confusion.</item>
                              </list>Call your healthcare provider if you get symptoms that may
be related to opioid withdrawal including tremors, chills, diarrhea,
irritability, and yawning.<br/>
                              <br/>These are not all
the possible side effects of TARGINIQ ER.  Call your doctor for medical
advice about side effects.  You may report side effects to FDA at
1-800-FDA-1088.  <content styleCode="bold">For more information go to dailymed.nlm.nih.gov.</content>
                              <br/>
                              <br/>Manufactured by: Purdue Pharma L.P., Stamford,
CT 06901-3431, www.purduepharma.com or call 1-888-726-7535</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="p3279274341406747208">This Medication Guide
has been approved by the U.S. Food and Drug Administration.<br/>Issue:  12/2016</paragraph>
               </text>
               <effectiveTime value="20161222"/>
            </section>
         </component>
         <component>
            <section ID="gd0110969-0e7b-11ed-330e-584b18040109">
               <id root="5b76a4d2-fd1d-e29f-f2d1-32d89457be5a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph ID="p14422271406749872">Targiniq
ER 10 mg/5 mg<br/>NDC: 59011-520-01</paragraph>
                  <renderMultiMedia referencedObject="g21422271406749709"/>
               </text>
               <effectiveTime value="20140731"/>
               <component>
                  <observationMedia ID="g21422271406749709">
                     <text>Targiniq 10 mg/5 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="Targiniq 10 mg lab_v9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s183281406750609">
               <id root="8c8e24b3-0247-77f9-41de-d4690070388b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph ID="p2813281406750619">Targiniq ER 20 mg/10 mg<br/>NDC: 59011-521-01</paragraph>
                  <renderMultiMedia referencedObject="g254281406750293"/>
               </text>
               <effectiveTime value="20140731"/>
               <component>
                  <observationMedia ID="g254281406750293">
                     <text>Targiniq ER 20 mg/10 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="Targiniq 20 mg lab_v9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s254281406750658">
               <id root="0959828d-ff94-c8ad-ce31-0716684036c9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph ID="p399281406750662">Targiniq ER 40 mg/20 mg<br/>NDC: 59011-522-01</paragraph>
                  <renderMultiMedia referencedObject="g254281406750424"/>
               </text>
               <effectiveTime value="20140731"/>
               <component>
                  <observationMedia ID="g254281406750424">
                     <text>Targiniq ER 40 mg/20 mg</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="Targiniq 40 mg lab_v9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>